{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,20]],"date-time":"2026-10-20T20:31:12Z","timestamp":1792528272162,"version":"4.5.0"},"reference-count":336,"publisher":"Wiley","issue":"8","content-domain":{"domain":["wiley.com","cochranelibrary.com"],"crossmark-restriction":true},"short-container-title":[],"DOI":"10.1002\/14651858.cd015855","type":"journal-article","created":{"date-parts":[[2025,8,11]],"date-time":"2025-08-11T10:31:38Z","timestamp":1754908298000},"update-policy":"https:\/\/doi.org\/10.1002\/crossmark_policy","source":"Crossref","is-referenced-by-count":8,"title":["Non-targeted immunosuppressive and immunomodulatory therapies for idiopathic inflammatory myopathies"],"prefix":"10.1002","volume":"2025","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-3658-2001","authenticated-orcid":false,"given":"Joost","family":"Raaphorst","sequence":"additional","affiliation":[{"name":"Department of Neurology, Amsterdam Neuroscience; Amsterdam UMC, University of Amsterdam; Amsterdam Netherlands"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-8970-4116","authenticated-orcid":false,"given":"Nicola J","family":"Gullick","sequence":"additional","affiliation":[{"name":"Rheumatology; University Hospitals Coventry and Warwickshire NHS Trust; Coventry UK"},{"name":"Institute for Precision Diagnostics and Translational Medicine; University Hospitals Coventry & Warwickshire; Coventry UK"},{"name":"Warwick Medical School; University of Warwick; Coventry UK"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Farhad","family":"Shokraneh","sequence":"additional","affiliation":[{"name":"Centre for Academic Primary Care, Population Health Sciences, Bristol Medical School; University of Bristol; Bristol UK"},{"name":"Centre for Tropical Medicine and Global Health, Nuffield Department of Clinical Medicine; University of Oxford; Oxford UK"},{"name":"Cochrane Neuromuscular; University College London Hospitals; London UK"},{"name":"Institute of Health Informatics; University College London; London UK"},{"name":"Department of Evidence Synthesis; Systematic Review Consultants LTD; Oxford UK"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ruth","family":"Brassington","sequence":"additional","affiliation":[{"name":"Cochrane Neuromuscular, Queen Square Centre for Neuromuscular Diseases; National Hospital for Neurology and Neurosurgery, University College London Hospitals; London UK"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Minoesch","family":"Min","sequence":"additional","affiliation":[{"name":"Emergency Department; Isala Hospital; Zwolle Netherlands"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Saadia S","family":"Ali","sequence":"additional","affiliation":[{"name":"Department of Rheumatology; Kings College Hospital; London UK"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-9301-0520","authenticated-orcid":false,"given":"Patrick A","family":"Gordon","sequence":"additional","affiliation":[{"name":"Department of Rheumatology; Kings College Hospital; London UK"},{"name":"School of Immunology & Microbial Sciences; King's College London; London UK"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"311","published-online":{"date-parts":[[2025,8,11]]},"reference":[{"issue":"3","key":"10.1002\/14651858.CD015855-BIB0001|cit1","doi-asserted-by":"crossref","first-page":"365","DOI":"10.7326\/0003-4819-92-3-365","article-title":"Azathioprine with prednisone for polymyositis. A controlled, clinical trial","volume":"92","author":"Bunch","year":"1980","journal-title":"Annals of Internal Medicine"},{"issue":"17","key":"10.1002\/14651858.CD015855-BIB0002|cit2","first-page":"645","article-title":"High dose intravenous immunoglobulin infusion in the treatment of dermatomyositis","volume":"119","year":"1994","journal-title":"Deutsche Medizinische Wochenschrift (1946)"},{"issue":"5","key":"10.1002\/14651858.CD015855-BIB0003|cit3","doi-asserted-by":"crossref","first-page":"1729","DOI":"10.1172\/JCI117520","article-title":"High-dose intravenous immunoglobulin exerts its beneficial effect in patients with dermatomyositis by blocking endomysial deposition of activated complement fragments","volume":"94","author":"Basta","year":"1994","journal-title":"Journal of Clinical Investigation"},{"issue":"27","key":"10.1002\/14651858.CD015855-BIB0004|cit4","doi-asserted-by":"crossref","first-page":"1993","DOI":"10.1056\/NEJM199312303292704","article-title":"A controlled trial of high-dose intravenous immune globulin infusions as treatment for dermatomyositis","volume":"329","author":"Dalakas","year":"1993","journal-title":"New England Journal of Medicine"},{"issue":"3","key":"10.1002\/14651858.CD015855-BIB0005|cit5","doi-asserted-by":"crossref","first-page":"255","DOI":"10.1385\/CRIAI:29:3:255","article-title":"Intravenous immunoglobulin in patients with anti-GAD antibody-associated neurological diseases and patients with inflammatory myopathies: effects on clinicopathological features and immunoregulatory genes","volume":"29","author":"Dalakas","year":"2005","journal-title":"Clinical Reviews in Allergy and Immunology"},{"key":"10.1002\/14651858.CD015855-BIB0006|cit6","first-page":"728","article-title":"Treatment of juvenile dermatomyositis (JDM) with high dose oral steroids or with steroid pulses and low dose oral steroids","volume":"59","author":"Huppertz","year":"2000","journal-title":"Annals of the Rheumatic Diseases"},{"issue":"5","key":"10.1002\/14651858.CD015855-BIB0007|cit7","first-page":"392","article-title":"Treatment of juvenile dermatomyositis (JDM) with high-dose oral steroids (hoS) or with steroid pulse therapy plus low-dose oral steroids (SPT)","volume":"60","author":"Huppertz","year":"2001","journal-title":"Zeitschrift fur Rheumatologie"},{"key":"10.1002\/14651858.CD015855-BIB0008|cit8","unstructured":"Dexa-Myositis Trial: treatment of polymyositis and dermatomyositis - dexamethasone versus prednisone https:\/\/trialsearch.who.int\/Trial2.aspx?TrialID=ISRCTN48188950 2005"},{"key":"10.1002\/14651858.CD015855-BIB0009|cit9","unstructured":"Dexa-Myositis Trial https:\/\/trialsearch.who.int\/Trial2.aspx?TrialID=NTR169 2005"},{"issue":"2","key":"10.1002\/14651858.CD015855-BIB0010|cit10","first-page":"155","article-title":"Oral dexamethasone pulse therapy versus daily prednisone in subacute inflammatory myopathies: a randomized clinical trial","volume":"71","author":"Van De Vlekkert","year":"2008","journal-title":"Neurology"},{"issue":"6","key":"10.1002\/14651858.CD015855-BIB0011|cit11","doi-asserted-by":"crossref","first-page":"382","DOI":"10.1016\/j.nmd.2010.03.011","article-title":"Oral dexamethasone pulse therapy versus daily prednisolone in sub-acute onset myositis, a randomised clinical trial","volume":"20","author":"de Vlekkert","year":"2010","journal-title":"Neuromuscular Disorders"},{"key":"10.1002\/14651858.CD015855-BIB0012|cit12","unstructured":"Efficacy and safety of a human normal immunoglobulin product for intravenous administration (IVIg) in the treatment of dermatomyositis (DM) and polymyositis (PM): prospective, randomised, double-blind, placebo-controlled study https:\/\/trialsearch.who.int\/Trial2.aspx?TrialID=EUCTR2005-002463-88-AT 2016"},{"key":"10.1002\/14651858.CD015855-BIB0013|cit13","unstructured":"Efficacy and safety of a human normal immunoglobulin product for intravenous administration (IVIg) in the treatment of dermatomyositis (DM) and polymyositis (PM): prospective, randomised, double-blind, placebo-controlled study https:\/\/clinicaltrialsregister.eu\/ctr-search\/trial\/2005-002463-88\/DE 2005"},{"key":"10.1002\/14651858.CD015855-BIB0014|cit14","unstructured":"Efficacy and safety of L0133 in the treatment of dermatomyositis and polymyositis: prospective, randomised, double-blind, placebo-controlled study https:\/\/trialsearch.who.int\/Trial2.aspx?TrialID=ISRCTN87782942 2006"},{"issue":"1","key":"10.1002\/14651858.CD015855-BIB0015|cit15","first-page":"A4560","article-title":"Efficacy of combination therapy with prednisolone and calcineurin inhibitor in patients with myositis-associated interstitial lung disease","volume":"201","author":"Fujisawa","year":"2020","journal-title":"American Journal of Respiratory and Critical Care Medicine"},{"issue":"4","key":"10.1002\/14651858.CD015855-BIB0016|cit16","doi-asserted-by":"crossref","first-page":"370","DOI":"10.1111\/resp.13978","article-title":"Prednisolone and tacrolimus versus prednisolone and cyclosporin A to treat polymyositis\/dermatomyositis-associated ILD: a randomized, open-label trial","volume":"26","author":"Fujisawa","year":"2020","journal-title":"Respirology"},{"key":"10.1002\/14651858.CD015855-BIB0017|cit17","unstructured":"Comparison of efficacy between tacrolimus and cyclosporine for the treatment of polymyositis\/dermatomyositis-associated interstitial lung disease https:\/\/center6.umin.ac.jp\/cgi-open-bin\/ctr_e\/ctr_view.cgi?recptno=R000017951 2014"},{"key":"10.1002\/14651858.CD015855-BIB0018|cit18","first-page":"43S, Abstract N","article-title":"Randomized, double-blind trial of plasma exchange, leukapheresis and sham apheresis in patients with polymyositis\/dermatomyositis (PM\/DM)","volume":"31","author":"Leitman","year":"1991","journal-title":"Transfusion"},{"issue":"21","key":"10.1002\/14651858.CD015855-BIB0019|cit19","doi-asserted-by":"crossref","first-page":"1380","DOI":"10.1056\/NEJM199205213262102","article-title":"Controlled trial of plasma exchange and leukapheresis in polymyositis and dermatomyositis","volume":"326","author":"Miller","year":"1992","journal-title":"New England Journal of Medicine"},{"key":"10.1002\/14651858.CD015855-BIB0020|cit20","first-page":"S53","article-title":"Randomised double blind controlled trial of methotrexate and steroids compared with azathioprine and steroids in the treatment of idiopathic inflammatory myopathy","volume":"199","author":"Miller","year":"2002","journal-title":"Journal of the Neurological Sciences"},{"issue":"2","key":"10.1002\/14651858.CD015855-BIB0021|cit21","first-page":"222, Abstract N","article-title":"Randomised double blind trial of methotrexate and steroids compared with azathioprine and steroids in the treatment of idiopathic inflammatory myopathy","volume":"72","author":"Miller","year":"2002","journal-title":"Journal of Neurology Neurosurgery and Psychology"},{"issue":"3","key":"10.1002\/14651858.CD015855-BIB0022|cit22","doi-asserted-by":"crossref","first-page":"382","DOI":"10.3109\/s10165-011-0534-4","article-title":"Effects of intravenous immunoglobulin therapy in Japanese patients with polymyositis and dermatomyositis resistant to corticosteroids: a randomized double-blind placebo-controlled trial","volume":"22","author":"Miyasaka","year":"2012","journal-title":"Modern Rheumatology"},{"key":"10.1002\/14651858.CD015855-BIB0023|cit23","unstructured":"Efficacy and safety study of GB-0998 for treatment of steroid-resistant polymyositis and dermatomyositis (PM\/DM) https:\/\/clinicaltrials.gov\/ct2\/show\/NCT00335985"},{"key":"10.1002\/14651858.CD015855-BIB0024|cit24","unstructured":"Double-blind, randomized, placebo-controlled phase III study evaluating efficacy and safety of subcutaneous human immunoglobulin (Octanorm) in patients with dermatomyositis https:\/\/www.clinicaltrialsregister.eu\/ctr-search\/trial\/2017-002710-31\/DE 2018"},{"key":"10.1002\/14651858.CD015855-BIB0025|cit25","unstructured":"Efficacy and safety of Octanorm in patients with dermatomyositis https:\/\/www.isrctn.com\/ISRCTN11520709 2018"},{"key":"10.1002\/14651858.CD015855-BIB0026|cit26","unstructured":"Study Evaluating efficacy and safety of Octanorm in patients with dermatomyositis https:\/\/clinicaltrials.gov\/ct2\/show\/NCT03686969"},{"issue":"10038","key":"10.1002\/14651858.CD015855-BIB0027|cit27","doi-asserted-by":"crossref","first-page":"2600","DOI":"10.1016\/S0140-6736(16)30845-5","article-title":"The PRINTO juvenile dermatomyositis trial","volume":"387","author":"Dale","year":"2016","journal-title":"Lancet"},{"key":"10.1002\/14651858.CD015855-BIB0028|cit28","unstructured":"Five year single-blind, phase III effectiveness randomised actively controlled clinical trial in new onset juvenile dermatomyositis:prednisone versus prednisone plus cyclosporine A versus prednisone plus mehotrexate https:\/\/clinicaltrialsregister.eu\/ctr-search\/trial\/2005-003956-37\/NL 2006"},{"key":"10.1002\/14651858.CD015855-BIB0029|cit29","unstructured":"Five year single blind, phase III effectiveness randomised actively controlled clinical trial in new onset juvenile dermatomyositis: prednisone versus prednisone plus cyclosporine A versus prednisone plus methotrexate https:\/\/trialsearch.who.int\/Trial2.aspx?TrialID=EUCTR2005-003956-37-SE 2006"},{"issue":"1","key":"10.1002\/14651858.CD015855-BIB0030|cit30","doi-asserted-by":"crossref","first-page":"24","DOI":"10.1186\/s12969-019-0326-5","article-title":"The PRINTO evidence-based proposal for glucocorticoids tapering\/discontinuation in new onset juvenile dermatomyositis patients","volume":"17","author":"Giancane","year":"2019","journal-title":"Pediatric Rheumatology"},{"key":"10.1002\/14651858.CD015855-BIB0031|cit31","first-page":"1717","article-title":"Comparison of the PRINTO 2010 and PRINTO\/International Myositis and Clinical Studies group (IMACS) 2016 improvement criteria in the PRINTO trial in new onset juvenile dermatomyositis","volume":"68","author":"Giancane","year":"2016","journal-title":"Arthritis and Rheumatology"},{"issue":"Suppl 1","key":"10.1002\/14651858.CD015855-BIB0032|cit32","first-page":"37 (Page 74 of","article-title":"Evidence based criteria for corticosteroid tapering\/discontinuation. An analysis of the PRINTO trial in new onset juvenile dermatomyositis","volume":"15","author":"Giancane","year":"2017","journal-title":"Pediatric Rheumatology"},{"key":"10.1002\/14651858.CD015855-BIB0033|cit33","first-page":"1711","article-title":"Evidence based criteria for corticosteroid tapering\/discontinuation. An analysis of the paediatric rheumatology international trials organization (PRINTO) trial in new onset juvenile dermatomyositis","volume":"68","author":"Giancane","year":"2016","journal-title":"Arthritis and Rheumatology"},{"key":"10.1002\/14651858.CD015855-BIB0034|cit34","first-page":"512","article-title":"Evidence based recommendations for corticosteroid tapering\/ discontinuation in new onset juvenile dermatomyositis patients: results from the paediatric rheumatology international trials organisation","volume":"70","author":"Giancane","year":"2018","journal-title":"Arthritis and Rheumatology"},{"key":"10.1002\/14651858.CD015855-BIB0035|cit35","doi-asserted-by":"crossref","first-page":"215","DOI":"10.1136\/annrheumdis-2018-eular.3750","article-title":"Evidence based recommendations for corticosteroid tapering\/discontinuation in new onset juvenile dermatomyositis patients from the PRINTO trial","volume":"77","author":"Giancane","year":"2018","journal-title":"Annals of the Rheumatic Diseases"},{"issue":"S10","key":"10.1002\/14651858.CD015855-BIB0036|cit36","first-page":"Abstract No. 29","article-title":"Evidence based recommendations for corticosteroid tapering\/discontinuation in new onset juvenile dermatomyositis patients from the PRINTO trial","volume":"69","author":"Giancane","year":"2017","journal-title":"Arthritis and Rheumatology"},{"key":"10.1002\/14651858.CD015855-BIB0037|cit37","first-page":"17","article-title":"Evidence based recommendations for corticosteroid tapering\/discontinuation in new onset juvenile dermatomyositis patients from the PRINTO trial","volume":"15","author":"Giancane","year":"2017","journal-title":"Pediatric Rheumatology"},{"key":"10.1002\/14651858.CD015855-BIB0038|cit38","first-page":"147","article-title":"Quality of life evaluation in new onset juvenile dermatomyositis patients from the PRINTO trial","volume":"15","author":"Guariento","year":"2017","journal-title":"Pediatric Rheumatology"},{"key":"10.1002\/14651858.CD015855-BIB0039|cit39","first-page":"Abstract No: 22","article-title":"Quality of life evaluation in new onset juvenile dermatomyositis patients from the PRINTO trial","volume":"69","author":"Guariento","year":"2017","journal-title":"Arthritis and Rheumatology"},{"issue":"Suppl 1","key":"10.1002\/14651858.CD015855-BIB0040|cit40","first-page":"37 (Page 73 of","article-title":"Comparison of the PRINTO 2010 and PRINTO\/IMACS 2016 improvement criteria in the PRINTO trial in new onset juvenile dermatomyositis","volume":"15","author":"Lavarello","year":"2017","journal-title":"Pediatric Rheumatology"},{"key":"10.1002\/14651858.CD015855-BIB0041|cit41","unstructured":"Five-year actively controlled clinical trial in new onset juvenile dermatomyositis https:\/\/clinicaltrials.gov\/ct2\/show\/NCT00323960 2006"},{"issue":"10038","key":"10.1002\/14651858.CD015855-BIB0042|cit42","doi-asserted-by":"crossref","first-page":"2601","DOI":"10.1016\/S0140-6736(16)30671-7","article-title":"The PRINTO juvenile dermatomyositis trial - Authors' reply","volume":"387","author":"Ruperto","year":"2016","journal-title":"Lancet"},{"issue":"Suppl 2","key":"10.1002\/14651858.CD015855-BIB0043|cit43","doi-asserted-by":"crossref","first-page":"O19","DOI":"10.1186\/1546-0096-11-S2-O19","article-title":"PReS-FINAL-2184: a randomized trial in new onset juvenile dermatomyositis: prednisone versus prednisone plus cyclosporine versus prednisone plus methotrexate","volume":"11","author":"Ruperto","year":"2013","journal-title":"Pediatric Rheumatology"},{"key":"10.1002\/14651858.CD015855-BIB0044|cit44","first-page":"S1042","article-title":"A randomized trial in new onset juvenile dermatomyositis: prednisone versus prednisone plus cyclosporine versus prednisone plus methotrexate","volume":"64","author":"Ruperto","year":"2012","journal-title":"Arthritis and Rheumatism"},{"issue":"10019","key":"10.1002\/14651858.CD015855-BIB0045|cit45","doi-asserted-by":"crossref","first-page":"671","DOI":"10.1016\/S0140-6736(15)01021-1","article-title":"Prednisone versus prednisone plus ciclosporin versus prednisone plus methotrexate in new-onset juvenile dermatomyositis: a randomised trial","volume":"387","author":"Ruperto","year":"2016","journal-title":"Lancet"},{"key":"10.1002\/14651858.CD015855-BIB0046|cit46","doi-asserted-by":"crossref","first-page":"A69","DOI":"10.1136\/annrheumdis-2013-eular.264","article-title":"A randomized trial in new onset juvenile dermatomyositis: prednisone versus prednisone plus cyclosporine versus prednisone plus methotrexate","volume":"72","author":"Ruperto","year":"2013","journal-title":"Annals of the Rheumatic Diseases"},{"key":"10.1002\/14651858.CD015855-BIB0047|cit47","doi-asserted-by":"crossref","first-page":"4","DOI":"10.1136\/annrheumdis-2021-eular.1389","article-title":"A randomized, double-blind, placebo controlled phase III trial of IVIg 10% in patients with dermatomyositis. The ProDERM study: results on efficacy and safety","volume":"80","author":"Aggarwal","year":"2021","journal-title":"Annals of the Rheumatic Diseases"},{"key":"10.1002\/14651858.CD015855-BIB0048|cit48","first-page":"S83","article-title":"Effect of octagam 10% IVIg versus placebo on clinical response in patients with dermatomyositis: the ProDERM randomized clinical trial","volume":"62","author":"Aggarwal","year":"2020","journal-title":"Muscle and Nerve"},{"key":"10.1002\/14651858.CD015855-BIB0049|cit49","first-page":"1918","article-title":"Efficacy and safety of IVIg (Octagam 10%) in patients with active dermatomyositis. Results of a randomized, double-blind, placebo-controlled phase III trial (ProDERM Study)","volume":"72","author":"Aggarwal","year":"2020","journal-title":"Arthritis and Rheumatology"},{"key":"10.1002\/14651858.CD015855-BIB0050|cit50","first-page":"1409","article-title":"Safety and tolerability of IVIG (Octagam 10%) in patients with active dermatomyositis. Results of a randomized, double-blind, placebo-controlled phase III trial","volume":"73","author":"Aggarwal","year":"2021","journal-title":"Arthritis and Rheumatology"},{"key":"10.1002\/14651858.CD015855-BIB0051|cit51","doi-asserted-by":"crossref","first-page":"S133","DOI":"10.1016\/j.nmd.2020.08.293","article-title":"The ProDERM study: a randomized, double-blinded, placebo controlled trial of IVIG (Octagam 10%) in patients with dermatomyositis","volume":"30","author":"Aggarwal","year":"2020","journal-title":"Neuromuscular Disorders"},{"issue":"18 Suppl","key":"10.1002\/14651858.CD015855-BIB0052|cit52","first-page":"P3","article-title":"The ProDERM study: safety and tolerability results from randomized, double-blind, placebo-controlled phase-III-trial in patients with dermatomyositis","volume":"98","author":"Aggarwal","year":"2022","journal-title":"Neurology"},{"issue":"14","key":"10.1002\/14651858.CD015855-BIB0053|cit53","doi-asserted-by":"crossref","first-page":"1264","DOI":"10.1056\/NEJMoa2117912","article-title":"Trial of intravenous immune globulin in dermatomyositis","volume":"387","author":"Aggarwal","year":"2022","journal-title":"New England Journal of Medicine"},{"issue":"1","key":"10.1002\/14651858.CD015855-BIB0054|cit54","doi-asserted-by":"crossref","first-page":"e23677","DOI":"10.1097\/MD.0000000000023677","article-title":"Prospective, double-blind, randomized, placebo-controlled phase III study evaluating efficacy and safety of octagam 10% in patients with dermatomyositis (\"ProDERM Study\")","volume":"100","author":"Aggarwal","year":"2021","journal-title":"Medicine"},{"key":"10.1002\/14651858.CD015855-BIB0055|cit55","first-page":"S10","article-title":"Evaluating efficacy and safety of a 10% intravenous immunoglobulin solution in patients with dermatomyositis (ProDERM study)-design of a phase III study","volume":"56","author":"Aggarwal","year":"2017","journal-title":"Muscle and Nerve"},{"key":"10.1002\/14651858.CD015855-BIB0056|cit56","first-page":"4449","article-title":"Effect of treatment with IVIG (octagam10%) on skin symptoms and quality of life in subjects with dermatomyositis. Results of a large, randomized, placebo-controlled international phase III trial","volume":"74","author":"Aggarwal","year":"2022","journal-title":"Arthritis and Rheumatology"},{"issue":"1","key":"10.1002\/14651858.CD015855-BIB0057|cit57","doi-asserted-by":"crossref","first-page":"94","DOI":"10.1056\/NEJMc2214285","article-title":"Trial of intravenous immune globulin in dermatomyositis. Reply","volume":"388","author":"Aggarwal","year":"2023","journal-title":"New England Journal of Medicine"},{"key":"10.1002\/14651858.CD015855-BIB0058|cit58","unstructured":"Study evaluating efficacy and safety of octagam 10% in patients with dermatomyositis (idiopathic inflammatory myopathy) https:\/\/clinicaltrials.gov\/ct2\/show\/NCT02728752 2017"},{"key":"10.1002\/14651858.CD015855-BIB0059|cit59","doi-asserted-by":"crossref","first-page":"AB53","DOI":"10.1016\/j.jaad.2022.06.245","article-title":"Efficacy of intravenous immunoglobulins (IVIG) in improving muscle and skin symptoms in dermatomyositis patients. Results of a large, randomized, placebo-controlled international phase III trial (ProDERM)","volume":"87","author":"Werth","year":"2022","journal-title":"Journal of the American Academy of Dermatology"},{"issue":"1","key":"10.1002\/14651858.CD015855-BIB0060|cit60","doi-asserted-by":"crossref","first-page":"94","DOI":"10.1056\/NEJMc2214285","article-title":"Trial of intravenous immune globulin in dermatomyositis","volume":"388","author":"Werth","year":"2023","journal-title":"New England Journal of Medicine"},{"key":"10.1002\/14651858.CD015855-BIB0061|cit61","unstructured":"A prospective, randomised, assessor-blind, multicenter study of efficacy and safety of combined treatment of methotrexate + glucocorticoids versus glucocorticoids alone in patients with polymyositis and dermatomyositis. - PROMETHEUS https:\/\/trialsearch.who.int\/Trial2.aspx?TrialID=EUCTR2007-004410-13-CZ 2007"},{"key":"10.1002\/14651858.CD015855-BIB0062|cit62","unstructured":"A prospective, randomised, assessor-blind, multicenter study of efficacy and safety of combined treatment of methotrexate + glucocorticoids versus glucocorticoids alone in patients with polymyositis and dermatomyositis. - PROMETHEUS https:\/\/trialsearch.who.int\/Trial2.aspx?TrialID=EUCTR2007-004410-13-SE 2008"},{"key":"10.1002\/14651858.CD015855-BIB0063|cit63","first-page":"2224","article-title":"Semi-quantitative and quantitative evaluation of magnetic resonance imaging in patients with idiopathic inflammatory myopathies-a subanalysis of the PROMETHEUS study","volume":"71","author":"Kubinova","year":"2019","journal-title":"Arthritis and Rheumatology"},{"key":"10.1002\/14651858.CD015855-BIB0064|cit64","doi-asserted-by":"crossref","first-page":"1018","DOI":"10.1136\/annrheumdis-2019-eular.7616","article-title":"Use of magnetic resonance imaging for assessment of patients with idiopathic inflammatory myopathies-a subanalysis of the PROMETHEUS study","volume":"78","author":"Kubinova","year":"2019","journal-title":"Annals of the Rheumatic Diseases"},{"key":"10.1002\/14651858.CD015855-BIB0065|cit65","doi-asserted-by":"crossref","first-page":"171","DOI":"10.1136\/annrheumdis-2014-eular.3886","article-title":"A prospective, randomized, open-label, assessor-blind, multicenter study of efficacy and safety of combined treatment of methotrexate + glucocorticoids versus glucocorticoids alone in patients with polymyositis and dermatomyositis (PROMETHEUS trial)","volume":"73","author":"Mann","year":"2014","journal-title":"Annals of the Rheumatic Diseases"},{"key":"10.1002\/14651858.CD015855-BIB0066|cit66","unstructured":"Combined treatment of methotrexate + glucocorticoids versus glucocorticoids alone in patients with PM and DM https:\/\/clinicaltrials.gov\/ct2\/show\/NCT00651040 2008"},{"issue":"Suppl 2","key":"10.1002\/14651858.CD015855-BIB0067|cit67","first-page":"171","article-title":"A prospective, randomized, open-label, assessor-blind, multicenter study of efficacy and safety of combined treatment of methotrexate + glucocorticoids versus glucocorticoids alone in patients with polymyositis and dermatomyositis (PROMETHEUS trial)","volume":"73","author":"Mann","year":"2014","journal-title":"Annals of the Rheumatic Diseases"},{"issue":"10","key":"10.1002\/14651858.CD015855-BIB0068|cit68","first-page":"S83","article-title":"One year randomised controlled trial of second line agents in myositis (SELAM): late additional immunosuppression is ineffective in patients who have partially responded to steroids","volume":"63","author":"Choy","year":"2011","journal-title":"Arthritis and Rheumatism"},{"key":"10.1002\/14651858.CD015855-BIB0069|cit69","first-page":"iii33-4","article-title":"One-year randomised controlled trial of second line agents in myositis (SELAM): additional immunosuppression is ineffective in patients who have partially responded to steroids","volume":"50","author":"Choy","year":"2011","journal-title":"Rheumatology"},{"key":"10.1002\/14651858.CD015855-BIB0070|cit70","unstructured":"Second line agents in myositis https:\/\/www.isrctn.com\/ISRCTN40085050 2002"},{"issue":"6","key":"10.1002\/14651858.CD015855-BIB0071|cit71","doi-asserted-by":"crossref","first-page":"1050-5","DOI":"10.1093\/rheumatology\/keu442","article-title":"Second-line agents in myositis: 1-year factorial trial of additional immunosuppression in patients who have partially responded to steroids","volume":"54","author":"Ibrahim","year":"2015","journal-title":"Rheumatology"},{"issue":"2","key":"10.1002\/14651858.CD015855-BIB0072|cit72","doi-asserted-by":"crossref","first-page":"95","DOI":"10.1080\/030097400750001897","article-title":"Cyclosporine A versus methotrexate in the treatment of polymyositis and dermatomyositis","volume":"29","author":"Vencovsky","year":"2000","journal-title":"Scandinavian Journal of Rheumatology"},{"issue":"3","key":"10.1002\/14651858.CD015855-BIB0073|cit73","doi-asserted-by":"crossref","first-page":"392-9","DOI":"10.1002\/1529-0131(199803)41:3<392::AID-ART3>3.0.CO;2-X","article-title":"Treatment of refractory myositis: a randomized crossover study of two new cytotoxic regimens","volume":"41","author":"Villalba","year":"1998","journal-title":"Arthritis and Rheumatism"},{"key":"10.1002\/14651858.CD015855-BIB0074|cit74","unstructured":"Abatacept treatment in polymyositis and dermatomyositis - ARTEMIS https:\/\/trialsearch.who.int\/Trial2.aspx?TrialID=EUCTR2009-015957-20-CZ 2010"},{"key":"10.1002\/14651858.CD015855-BIB0075|cit75","unstructured":"Abatacept treatment in polymyositis and dermatomyositis - ARTEMIS https:\/\/trialsearch.who.int\/Trial2.aspx?TrialID=EUCTR2009-015957-20-SE 2010"},{"issue":"S9","key":"10.1002\/14651858.CD015855-BIB0076|cit76","first-page":"Abstract No. 23","article-title":"Abatacept in the treatment of adult dermatomyositis and polymyositis: a randomized, treatment delayed-start trial","volume":"67","author":"Lundberg","year":"2015","journal-title":"Arthritis and Rheumatology"},{"key":"10.1002\/14651858.CD015855-BIB0077|cit77","unstructured":"Abatacept treatment in polymyositis and dermatomyositis https:\/\/clinicaltrials.gov\/ct2\/show\/NCT01315938 2011"},{"issue":"1","key":"10.1002\/14651858.CD015855-BIB0078|cit78","doi-asserted-by":"crossref","first-page":"e12732","DOI":"10.1111\/sji.12732","article-title":"Effect of CTLA4-Ig (abatacept) treatment on T cells and B cells in peripheral blood of patients with polymyositis and dermatomyositis","volume":"89","author":"Tang","year":"2019","journal-title":"Scandinavian Journal of Immunology"},{"key":"10.1002\/14651858.CD015855-BIB0079|cit79","doi-asserted-by":"crossref","first-page":"817","DOI":"10.1136\/annrheumdis-2015-eular.4518","article-title":"Abatacept in the treatment of adult dermatomyositis and polymyositis: artemis, a randomized, treatment delayed-start trial","volume":"74","author":"Tjarnlund","year":"2015","journal-title":"Annals of the Rheumatic Diseases"},{"issue":"1","key":"10.1002\/14651858.CD015855-BIB0080|cit80","doi-asserted-by":"crossref","first-page":"55","DOI":"10.1136\/annrheumdis-2017-211751","article-title":"Abatacept in the treatment of adult dermatomyositis and polymyositis: a randomised, phase IIb treatment delayed-start trial","volume":"77","author":"Tjarnlund","year":"2018","journal-title":"Annals of the Rheumatic Diseases"},{"issue":"1","key":"10.1002\/14651858.CD015855-BIB0081|cit81","doi-asserted-by":"crossref","first-page":"29","DOI":"10.1002\/jca.21399","article-title":"Effect of combined treatment with immunoadsorption and membrane filtration on plasma coagulation - results of a randomized controlled crossover study","volume":"31","author":"Biesenbach","year":"2016","journal-title":"Journal of Clinical Apheresis"},{"key":"10.1002\/14651858.CD015855-BIB0082|cit82","first-page":"910","article-title":"Safety and efficacy of belimumab in the treatment of adult idiopathic inflammatory myositis (polymyositis and dermatomyositis)","volume":"73","author":"Chadha","year":"2021","journal-title":"Arthritis and Rheumatology"},{"key":"10.1002\/14651858.CD015855-BIB0083|cit83","unstructured":"Belimumab in idiopathic inflammatory myositis https:\/\/clinicaltrials.gov\/ct2\/show\/NCT03215927 2015"},{"issue":"7","key":"10.1002\/14651858.CD015855-BIB0084|cit84","first-page":"294","article-title":"Clocortolone (Cl 68) versus fluocinolone, a double-blind, randomized lateral comparison","volume":"24","author":"Borelli","year":"1973","journal-title":"Der Hautarzt; Zeitschrift fur Dermatologie, Venerologie, und verwandte Gebiete"},{"issue":"11","key":"10.1002\/14651858.CD015855-BIB0085|cit85","doi-asserted-by":"crossref","first-page":"4445","DOI":"10.1093\/rheumatology\/keac101","article-title":"Branched chain amino acids in the treatment of polymyositis and dermatomyositis: a phase II\/III, multi-centre, randomized controlled trial","volume":"61","author":"Kimura","year":"2022","journal-title":"Rheumatology"},{"key":"10.1002\/14651858.CD015855-BIB0086|cit86","doi-asserted-by":"crossref","first-page":"846","DOI":"10.1136\/annrheumdis-2019-eular.5235","article-title":"Branched chain amino acids in the treatment of polymyositis and dermatomyositis: results from the BTOUGH study","volume":"78","author":"Kimura","year":"2019","journal-title":"Annals of the Rheumatic Diseases"},{"issue":"2","key":"10.1002\/14651858.CD015855-BIB0087|cit87","first-page":"270","article-title":"Plasma exchange in polymyositis and dermatomyositis: a multicenter study of 57 cases","volume":"13","author":"Cherin","year":"1995","journal-title":"Clinical and Experimental Rheumatology"},{"key":"10.1002\/14651858.CD015855-BIB0088|cit88","unstructured":"An observation of tofacitinib in patients of MDA5+ clinically amyopathic dermatomyositis with interstitial lung disease https:\/\/trialsearch.who.int\/Trial2.aspx?TrialID=ChiCTR1800016629 2018"},{"key":"10.1002\/14651858.CD015855-BIB0089|cit89","unstructured":"An open-label, randomized controlled trial for baratinib in the treatment of dermatomyositis https:\/\/trialsearch.who.int\/Trial2.aspx?TrialID=ChiCTR2000030591 2020"},{"key":"10.1002\/14651858.CD015855-BIB0090|cit90","unstructured":"A prospective, double-blind, positive control study of abatacept in the treatment of high-risk patients with dermatomyositis and rapidly progressing interstitial pneumonia https:\/\/trialsearch.who.int\/Trial2.aspx?TrialID=ChiCTR2000036282 2020"},{"key":"10.1002\/14651858.CD015855-BIB0091|cit91","unstructured":"Study on early warning of rapid progressive interstitial lung disease in dermatomyositis https:\/\/trialsearch.who.int\/Trial2.aspx?TrialID=ChiCTR2000036709 2020"},{"key":"10.1002\/14651858.CD015855-BIB0092|cit92","unstructured":"The safety and the efficacy study of allogenic adipose MSC-Exos in the treatment of anti-MDA5 positive dermatonyositis- associated interstitial lung disease https:\/\/trialsearch.who.int\/Trial2.aspx?TrialID=ChiCTR2100042948 2021"},{"key":"10.1002\/14651858.CD015855-BIB0093|cit93","unstructured":"An observation of Pirfenidone in patients with rapidly progressive interstitial lung disease secondary to clinically amyopathic dermatomyositis https:\/\/trialsearch.who.int\/Trial2.aspx?TrialID=ChiCTR-IPR-16007958 2016"},{"issue":"4","key":"10.1002\/14651858.CD015855-BIB0094|cit94","doi-asserted-by":"crossref","first-page":"550","DOI":"10.1016\/j.intimp.2005.11.016","article-title":"The role of high-dose immune globulin intravenous in the treatment of dermatomyositis","volume":"6","author":"Dalakas","year":"2006","journal-title":"International Immunopharmacology"},{"key":"10.1002\/14651858.CD015855-BIB0095|cit95","first-page":"397","article-title":"Sensitivity of three skin-specific efficacy outcomes to detect patientand physician-reported improvement in overall skin disease in dermatomyositis","volume":"74","author":"Dan","year":"2022","journal-title":"Arthritis and Rheumatology"},{"key":"10.1002\/14651858.CD015855-BIB0096|cit96","unstructured":"A study of safety and efficacy of lenabasum in dermatomyositis patients https:\/\/clinicaltrialsregister.eu\/ctr-search\/trial\/2018-003273-10\/DE 2018"},{"key":"10.1002\/14651858.CD015855-BIB0097|cit97","unstructured":"A study of safety and efficacy of lenabasum in dermatomyositis patients https:\/\/clinicaltrialsregister.eu\/ctr-search\/trial\/2018-003273-10\/GB 2018"},{"key":"10.1002\/14651858.CD015855-BIB0098|cit98","unstructured":"A study of safety and efficacy of lenabasum in dermatomyositis patients https:\/\/clinicaltrialsregister.eu\/ctr-search\/trial\/2018-003273-10\/HU 2019"},{"key":"10.1002\/14651858.CD015855-BIB0099|cit99","unstructured":"JBT101-DM-002 A phase 3 safety and efficacy study of lenabasum in dermatomyositis subjects https:\/\/rctportal.niph.go.jp\/en\/detail?trial_id=JapicCTI-194904 2019"},{"key":"10.1002\/14651858.CD015855-BIB0100|cit100","unstructured":"Trial to evaluate efficacy and safety of lenabasum in dermatomyositis https:\/\/clinicaltrials.gov\/ct2\/show\/NCT03813160 2018"},{"key":"10.1002\/14651858.CD015855-BIB0101|cit101","first-page":"3679","article-title":"Lenabasum reduces IFNgamma and pIRF3 in dermatomyositis skin: biomarker results from a double-blind phase 3 international randomized controlled trial","volume":"74","author":"Vazquez","year":"2022","journal-title":"Arthritis and Rheumatology"},{"key":"10.1002\/14651858.CD015855-BIB0102|cit102","doi-asserted-by":"crossref","first-page":"S12","DOI":"10.1016\/j.jid.2022.05.122","article-title":"Lenabasum reduces IFNgamma and pIRF3 in dermatomyositis skin: biomarker results from a double-blind phase 3 international randomized controlled trial","volume":"142","author":"Vazquez","year":"2022","journal-title":"Journal of Investigative Dermatology"},{"key":"10.1002\/14651858.CD015855-BIB0103|cit103","first-page":"3307","article-title":"Preliminary baseline subject demographics and disease characteristics in a phase 3 clinical trial of the safety and efficacy of lenabasum in dermatomyositis (DETERMINE)","volume":"72","author":"Werth","year":"2020","journal-title":"Arthritis and Rheumatology"},{"key":"10.1002\/14651858.CD015855-BIB0104|cit104","first-page":"323","article-title":"Cutaneous manifestations, clinical trials, safety efficacy and safety of lenabasum in the phase 3 DeterMine Trial in dermatomyositis","volume":"74","author":"Werth","year":"2022","journal-title":"Arthritis and Rheumatology"},{"key":"10.1002\/14651858.CD015855-BIB0105|cit105","doi-asserted-by":"crossref","first-page":"106","DOI":"10.1136\/annrheumdis-2022-eular.5037","article-title":"Efficacy and safety of lenabasum in the phase 3 determine trial in dermatomyositis","volume":"81","author":"Werth","year":"2022","journal-title":"Annals of the Rheumatic Diseases"},{"issue":"3","key":"10.1002\/14651858.CD015855-BIB0106|cit106","doi-asserted-by":"crossref","first-page":"434","DOI":"10.3899\/jrheum.191375","article-title":"The effect of creatine supplementation on muscle function in childhood myositis: a randomized, double-blind, placebo-controlled feasibility study","volume":"48","author":"Dover","year":"2021","journal-title":"Journal of Rheumatology"},{"key":"10.1002\/14651858.CD015855-BIB0107|cit107","unstructured":"Rituximab in the treatment of refractory adult and juvenile dermatomyositis (DM) and adult polymyositis (PM) - rituximab in myositis https:\/\/trialsearch.who.int\/Trial2.aspx?TrialID=EUCTR2006-000078-65-SE 2006"},{"key":"10.1002\/14651858.CD015855-BIB0108|cit108","unstructured":"A placebo-controlled, proof-of concept study of the efficacy of gevokizumab subcutaneously over 24 weeks in the treatment of patients with polymyositis, dermatomyositis or necrotizing autoimmune myopathy disease https:\/\/trialsearch.who.int\/Trial2.aspx?TrialID=EUCTR2012-005772-34-DE 2013"},{"key":"10.1002\/14651858.CD015855-BIB0109|cit109","unstructured":"A placebo-controlled, proof-of concept study of the efficacy of gevokizumab subcutaneously over 24 weeks in the treatment of patients with polymyositis, dermatomyositis or necrotizing autoimmune myopathy disease https:\/\/www.clinicaltrialsregister.eu\/ctr-search\/trial\/2012-005772-34\/SE 2013"},{"key":"10.1002\/14651858.CD015855-BIB0110|cit110","unstructured":"Multicentric, prospective open-label study to assess the efficacy and safety of tocilizumab in subjects with refractory myositis https:\/\/trialsearch.who.int\/Trial2.aspx?TrialID=EUCTR2018-000391-15-IT 2018"},{"key":"10.1002\/14651858.CD015855-BIB0111|cit111","unstructured":"A research study to collect long term safety information from subjects who have received study treatment from a qualifying lenabasum Corbus trial https:\/\/trialsearch.who.int\/Trial2.aspx?TrialID=EUCTR2020-001762-11-GB 2020"},{"key":"10.1002\/14651858.CD015855-BIB0112|cit112","unstructured":"A research study to collect long term safety information from subjects who have received study treatment from a qualifying lenabasum Corbus trial https:\/\/trialsearch.who.int\/Trial2.aspx?TrialID=EUCTR2020-001762-11-SE 2020"},{"key":"10.1002\/14651858.CD015855-BIB0113|cit113","unstructured":"Phase II placebo controlled study, to evaluate the efficacy and safety of begelomab in combination with standard immunosuppressive therapy and\/or corticosteroids in the treatment of patients with dermatomyositis https:\/\/trialsearch.who.int\/Trial2.aspx?TrialID=EUCTR2021-000898-83-IT 2021"},{"issue":"1","key":"10.1002\/14651858.CD015855-BIB0114|cit114","doi-asserted-by":"crossref","first-page":"24","DOI":"10.1186\/2045-9912-1-24","article-title":"Open-label trial and randomized, double-blind, placebo-controlled, crossover trial of hydrogen-enriched water for mitochondrial and inflammatory myopathies","volume":"1","author":"Ito","year":"2011","journal-title":"Medical Gas Research"},{"key":"10.1002\/14651858.CD015855-BIB0115|cit115","unstructured":"A phase II\/III, randomized, double-blind, placebo-controlled study and open active-treatment extension study to assess the efficacy and safety of the branch chain amino acids (BCAAs) in polymyositis and dermatomyositis https:\/\/trialsearch.who.int\/Trial2.aspx?TrialID=JPRN-UMIN000016233 2015"},{"key":"10.1002\/14651858.CD015855-BIB0116|cit116","unstructured":"Efficacy and safety of combination therapy of corticosteroid and tacrolimus for patients with anti-melanoma differentiation antigen 5 antibody-positive dermatomyositis-associated interstitial lung disease: a prospective multicenter clinical trial https:\/\/trialsearch.who.int\/Trial2.aspx?TrialID=JPRN-UMIN000032193 2018"},{"key":"10.1002\/14651858.CD015855-BIB0117|cit117","unstructured":"Investigation on the safety and utility of apremilast for the treatment of refractory rash in patients with dermatomyositis https:\/\/trialsearch.who.int\/Trial2.aspx?TrialID=jRCTs031200005 2020"},{"issue":"1","key":"10.1002\/14651858.CD015855-BIB0118|cit118","doi-asserted-by":"crossref","first-page":"118","DOI":"10.1111\/1346-8138.16179","article-title":"Evaluation of apremilast, an oral phosphodiesterase 4 inhibitor, for refractory cutaneous dermatomyositis: a phase 1b clinical trial","volume":"49","author":"Konishi","year":"2022","journal-title":"Journal of Dermatology"},{"key":"10.1002\/14651858.CD015855-BIB0119|cit119","unstructured":"Safety and effectiveness of h5G1.1-mAb for dermatomyositis https:\/\/clinicaltrials.gov\/ct2\/show\/NCT00005571 2000"},{"key":"10.1002\/14651858.CD015855-BIB0120|cit120","first-page":"Abstract No: 20","article-title":"A randomized, double-blind, placebo-controlled trial of infliximab in patients with polymyositis and dermatomyositis","volume":"58","author":"Coyle","year":"2008","journal-title":"Arthritis and Rheumatism"},{"key":"10.1002\/14651858.CD015855-BIB0121|cit121","unstructured":"Infliximab (Remicade) to treat dermatomyositis and polymyositis https:\/\/clinicaltrials.gov\/ct2\/show\/NCT00033891 2002"},{"issue":"6","key":"10.1002\/14651858.CD015855-BIB0122|cit122","doi-asserted-by":"crossref","first-page":"858","DOI":"10.1016\/j.semarthrit.2017.10.010","article-title":"A randomized, double-blind, placebo-controlled trial of infliximab in refractory polymyositis and dermatomyositis","volume":"47","author":"Schiffenbauer","year":"2018","journal-title":"Seminars in Arthritis and Rheumatism"},{"key":"10.1002\/14651858.CD015855-BIB0123|cit123","unstructured":"Understanding the pathogenesis and treatment of childhood onset dermatomyositis https:\/\/clinicaltrials.gov\/ct2\/show\/NCT00035958 2002"},{"issue":"3","key":"10.1002\/14651858.CD015855-BIB0124|cit124","doi-asserted-by":"crossref","first-page":"427","DOI":"10.1002\/ana.22477","article-title":"A randomized, pilot trial of etanercept in dermatomyositis","volume":"70","author":"Muscle Study Group","year":"2011","journal-title":"Annals of Neurology"},{"key":"10.1002\/14651858.CD015855-BIB0125|cit125","unstructured":"A pilot study of etanercept in dermatomyositis https:\/\/clinicaltrials.gov\/ct2\/show\/NCT00112385 2006"},{"issue":"4","key":"10.1002\/14651858.CD015855-BIB0126|cit126","doi-asserted-by":"crossref","first-page":"686","DOI":"10.1093\/rheumatology\/ket413","article-title":"Suppression of soluble T cell-associated proteins by an anti-interferon-alpha monoclonal antibody in adult patients with dermatomyositis or polymyositis","volume":"53","author":"Guo","year":"2014","journal-title":"Rheumatology"},{"key":"10.1002\/14651858.CD015855-BIB0127|cit127","first-page":"S93","article-title":"Proteomics study of a phase 1b trial with an anti-IFN-> monoclonal antibody indicates association of soluble interleukin 2 receptor with type I interferon activity in patients with dermatomyositis or polymyositis","volume":"64","author":"Guo","year":"2012","journal-title":"Arthritis and Rheumatism"},{"key":"10.1002\/14651858.CD015855-BIB0128|cit128","first-page":"S325","article-title":"Sifalimumab, an anti-IFN-alpha monoclonal antibody shows target suppression of a type I IFN signature in blood and muscle of dermatomyositis and polymyositis patients","volume":"64","author":"Higgs","year":"2012","journal-title":"Arthritis and Rheumatism"},{"issue":"1","key":"10.1002\/14651858.CD015855-BIB0129|cit129","doi-asserted-by":"crossref","first-page":"256","DOI":"10.1136\/annrheumdis-2012-202794","article-title":"A phase 1b clinical trial evaluating sifalimumab, an anti-IFN-alpha monoclonal antibody, shows target neutralisation of a type I IFN signature in blood of dermatomyositis and polymyositis patients","volume":"73","author":"Higgs","year":"2014","journal-title":"Annals of the Rheumatic Diseases"},{"key":"10.1002\/14651858.CD015855-BIB0130|cit130","unstructured":"A study to evaluate safety of multi-dose MEDI-545 in adult patients with dermatomyositis or polymyositis https:\/\/clinicaltrials.gov\/ct2\/show\/NCT00533091 2008"},{"key":"10.1002\/14651858.CD015855-BIB0131|cit131","first-page":"S403","article-title":"The selective sphingosine-1-phosphate receptor 1\/5 modulator siponimod (BAF312) shows beneficial effects in patients with active, treatment refractory polymyositis and dermatomyositis: a phase IIA proof-of-concept, double-blind, randomized trial","volume":"66","author":"Danko","year":"2014","journal-title":"Arthritis and Rheumatology"},{"key":"10.1002\/14651858.CD015855-BIB0132|cit132","unstructured":"A multi-centre, double-blind, placebo controlled, proof of concept study to evaluate the efficacy and tolerability of BAF312 in patients with polymyositis and dermatomyositis clinicaltrialsregister.eu\/ctr-search\/trial\/2008-006311-21\/GB 2009"},{"key":"10.1002\/14651858.CD015855-BIB0133|cit133","unstructured":"A multi-centre, double-blind, placebo controlled, proof of concept study to evaluate the efficacy and tolerability of BAF312 in patients with polymyositis and dermatomyositis https:\/\/trialsearch.who.int\/Trial2.aspx?TrialID=EUCTR2008-006311-21-HU 2009"},{"key":"10.1002\/14651858.CD015855-BIB0134|cit134","unstructured":"Efficacy and tolerability of BAF312 in patients with polymyositis and dermatomyositis https:\/\/clinicaltrials.gov\/ct2\/show\/NCT01148810 2010"},{"key":"10.1002\/14651858.CD015855-BIB0135|cit135","unstructured":"Study of efficacy and tolerability for BAF312 compared to placebo in patients with polymyositis https:\/\/trialsearch.who.int\/Trial2.aspx?TrialID=EUCTR2012-002859-42-BE 2014"},{"key":"10.1002\/14651858.CD015855-BIB0136|cit136","unstructured":"Study of efficacy and tolerability for BAF312 compared to placebo in patients with polymyositis https:\/\/clinicaltrialsregister.eu\/ctr-search\/trial\/2012-002859-42\/HU 2012"},{"key":"10.1002\/14651858.CD015855-BIB0137|cit137","unstructured":"Efficacy and tolerability of BAF312 in patients with polymyositis https:\/\/clinicaltrials.gov\/ct2\/show\/NCT01801917 2013"},{"key":"10.1002\/14651858.CD015855-BIB0138|cit138","unstructured":"Study of efficacy and tolerability for BAF312 compared to placebo in patients with active dermatomyositis https:\/\/www.clinicaltrialsregister.eu\/ctr-search\/trial\/2013-001799-39\/HU 2013"},{"key":"10.1002\/14651858.CD015855-BIB0139|cit139","unstructured":"Study of efficacy and tolerability for BAF312 compared to placebo in patients with active dermatomyositis https:\/\/trialsearch.who.int\/Trial2.aspx?TrialID=EUCTR2013-001799-39-PL 2014"},{"key":"10.1002\/14651858.CD015855-BIB0140|cit140","unstructured":"Safety and efficacy of BAF312 in dermatomyositis https:\/\/rctportal.niph.go.jp\/en\/detail?trial_id=JapicCTI-142590 2014"},{"key":"10.1002\/14651858.CD015855-BIB0141|cit141","unstructured":"Safety and efficacy of BAF312 in dermatomyositis https:\/\/clinicaltrials.gov\/ct2\/show\/NCT02029274 2013"},{"key":"10.1002\/14651858.CD015855-BIB0142|cit142","first-page":"1922","article-title":"Tocilizumab in myositis: results of a phase IIb double-blind randomized controlled trial","volume":"72","author":"Aggarwal","year":"2020","journal-title":"Arthritis and Rheumatology"},{"key":"10.1002\/14651858.CD015855-BIB0143|cit143","unstructured":"Tocilizumab in the treatment of refractory polymyositis and dermatomyositis https:\/\/clinicaltrials.gov\/ct2\/show\/NCT02043548 2014"},{"issue":"11","key":"10.1002\/14651858.CD015855-BIB0144|cit144","doi-asserted-by":"crossref","first-page":"983","DOI":"10.1002\/acr2.11493","article-title":"Randomized trial of tocilizumab in the treatment of refractory adult polymyositis and dermatomyositis","volume":"4","author":"Oddis","year":"2022","journal-title":"ACR Open Rheumatology"},{"key":"10.1002\/14651858.CD015855-BIB0145|cit145","first-page":"396","article-title":"Cutaneous Dermatomyositis Disease Area and Severity Index Activity Score (CDASI-A) and associated patient-reported outcomes and biomarkers in a phase 2 clinical trial in dermatomyositis (DM)","volume":"74","author":"Dan","year":"2022","journal-title":"Arthritis and Rheumatology"},{"key":"10.1002\/14651858.CD015855-BIB0146|cit146","unstructured":"Safety, tolerability, and efficacy of JBT-101 in subjects with dermatomyositis https:\/\/clinicaltrials.gov\/ct2\/show\/NCT02466243 2015"},{"key":"10.1002\/14651858.CD015855-BIB0147|cit147","first-page":"3357","article-title":"Lenabasum, a cannabinoid type 2 receptor agonist, reduces T-cell population and downregulates type 1 and 2 interferon activities in lesional dermatomyositis skin","volume":"70","author":"Reddy","year":"2018","journal-title":"Arthritis and Rheumatology"},{"key":"10.1002\/14651858.CD015855-BIB0148|cit148","doi-asserted-by":"crossref","first-page":"383","DOI":"10.1136\/annrheumdis-2021-eular.2048","article-title":"Long-term safety and efficacy of lenabasum during 3 years in an open-label extension (OLE) of a phase 2 study of lenabasum in refractory skin disease in dermatomyositis (DM)","volume":"80","author":"Werth","year":"2021","journal-title":"Annals of the Rheumatic Diseases"},{"key":"10.1002\/14651858.CD015855-BIB0149|cit149","doi-asserted-by":"crossref","first-page":"1228","DOI":"10.1136\/annrheumdis-2019-eular.6094","article-title":"Design of phase 3 study of lenabasum for the treatment of dermatomyositis","volume":"78","author":"Werth","year":"2019","journal-title":"Annals of the Rheumatic Diseases"},{"key":"10.1002\/14651858.CD015855-BIB0150|cit150","first-page":"5044","article-title":"Safety and efficacy of lenabasum at week 68 in an open-label extension of a phase 2 study of lenabasum in refractory skin-predominant dermatomyositis (DM) subjects","volume":"71","author":"Werth","year":"2019","journal-title":"Arthritis and Rheumatology"},{"key":"10.1002\/14651858.CD015855-BIB0151|cit151","doi-asserted-by":"crossref","first-page":"199","DOI":"10.1136\/annrheumdis-2019-eular.3397","article-title":"Safety and efficacy of lenabasum in an open-label extension of a phase 2 study of lenabasum in refractory skin-predominant dermatomyositis (DM) subjects","volume":"78","author":"Werth","year":"2019","journal-title":"Annals of the Rheumatic Diseases"},{"issue":"5","key":"10.1002\/14651858.CD015855-BIB0152|cit152","doi-asserted-by":"crossref","first-page":"S103","DOI":"10.1016\/j.jid.2018.03.613","article-title":"Study of safety and efficacy of lenabasum, a cannabinoid receptor type 2 agonist, in refractory skin-predominant dermatomyositis","volume":"138","author":"Werth","year":"2018","journal-title":"Journal of Investigative Dermatology"},{"issue":"10","key":"10.1002\/14651858.CD015855-BIB0153|cit153","doi-asserted-by":"crossref","first-page":"2651","DOI":"10.1016\/j.jid.2022.03.029","article-title":"Safety and efficacy of lenabasum, a cannabinoid receptor type 2 agonist, in patients with dermatomyositis with refractory skin disease: a randomized clinical trial","volume":"142","author":"Werth","year":"2022","journal-title":"Journal of Investigative Dermatology"},{"key":"10.1002\/14651858.CD015855-BIB0154|cit154","doi-asserted-by":"crossref","first-page":"763","DOI":"10.1136\/annrheumdis-2018-eular.3531","article-title":"A phase 2 study of safety and efficacy of lenabasum (JBT-101), a cannabinoid receptor type 2 agonist, in refractory skin predominant dermatomyositis","volume":"77","author":"Werth","year":"2018","journal-title":"Annals of the Rheumatic Diseases"},{"issue":"S10","key":"10.1002\/14651858.CD015855-BIB0155|cit155","first-page":"Abstract No. 21","article-title":"Comparison of patients with dermatomyositis in a specialty clinic versus clinical trial with anabasum (JBT-101), a cannabinoid receptor type 2 agonist","volume":"69","author":"Werth","year":"2017","journal-title":"Arthritis and Rheumatology"},{"key":"10.1002\/14651858.CD015855-BIB0156|cit156","doi-asserted-by":"crossref","first-page":"1111","DOI":"10.1136\/annrheumdis-2018-eular.5629","article-title":"Safety and efficacy of lenabasum in refractory skin-predominant dermatomyositis subjects treated in an open label extension of trial JBT101-DM-001","volume":"77","author":"Werth","year":"2018","journal-title":"Annals of the Rheumatic Diseases"},{"key":"10.1002\/14651858.CD015855-BIB0157|cit157","first-page":"2525","article-title":"Safety and efficacy of lenabasum in refractory skin-predominant dermatomyositis subjects treated on an open-label extension of trial JBT101-DM-001","volume":"70","author":"Werth","year":"2018","journal-title":"Arthritis and Rheumatology"},{"issue":"5","key":"10.1002\/14651858.CD015855-BIB0158|cit158","doi-asserted-by":"crossref","first-page":"S105","DOI":"10.1016\/j.jid.2019.03.686","article-title":"Safety and efficacy of lenabasum in refractory skin-predominant dermatomyositis subjects treated on an open-label extension of trial JBT101-DM-001","volume":"139","author":"Werth","year":"2019","journal-title":"Journal of Investigative Dermatology"},{"key":"10.1002\/14651858.CD015855-BIB0159|cit159","unstructured":"A phase 2 study of IMO-8400 in patients with dermatomyositis https:\/\/www.clinicaltrialsregister.eu\/ctr-search\/trial\/2015-003277-15\/GB 2015"},{"key":"10.1002\/14651858.CD015855-BIB0160|cit160","unstructured":"A phase 2 study of IMO-8400 in patients with dermatomyositis https:\/\/www.clinicaltrialsregister.eu\/ctr-search\/trial\/2015-003277-15\/HU 2016"},{"key":"10.1002\/14651858.CD015855-BIB0161|cit161","unstructured":"A phase 2 study of IMO-8400 in patients with dermatomyositis https:\/\/www.clinicaltrialsregister.eu\/ctr-search\/trial\/2015-003277-15\/SE 2016"},{"key":"10.1002\/14651858.CD015855-BIB0162|cit162","doi-asserted-by":"crossref","first-page":"1119","DOI":"10.1136\/annrheumdis-2016-eular.5174","article-title":"Design of a randomized, double-blind, placebo-controlled phase 2 clinical trial of the toll-like receptor antagonist IMO-8400 in patients with dermatomyositis","volume":"75","author":"Gordon","year":"2016","journal-title":"Annals of the Rheumatic Diseases"},{"key":"10.1002\/14651858.CD015855-BIB0163|cit163","first-page":"S57","article-title":"Rationale for toll-like receptor antagonism as a potential novel therapeutic approach for dermatomyositis","volume":"3","author":"Gruis","year":"2016","journal-title":"Journal of Neuromuscular Diseases"},{"issue":"9","key":"10.1002\/14651858.CD015855-BIB0164|cit164","doi-asserted-by":"crossref","first-page":"B18","DOI":"10.1016\/j.jid.2019.06.082","article-title":"LB1115 A double-blind, placebo-controlled, phase 2 trial of IMO-8400, a novel toll-like receptor 7\/8\/9 antagonist, in dermatomyositis","volume":"139","author":"Kim","year":"2019","journal-title":"Journal of Investigative Dermatology"},{"key":"10.1002\/14651858.CD015855-BIB0165|cit165","first-page":"5039","article-title":"A double-blind, placebo-controlled, phase 2 trial of a novel toll-like receptor 7\/8\/9 antagonist (Imo-8400) in dermatomyositis","volume":"71","author":"Kim","year":"2019","journal-title":"Arthritis and Rheumatology"},{"issue":"4","key":"10.1002\/14651858.CD015855-BIB0166|cit166","doi-asserted-by":"crossref","first-page":"1160","DOI":"10.1016\/j.jaad.2020.07.122","article-title":"A phase 2, double-blinded, placebo-controlled trial of toll-like receptor 7\/8\/9 antagonist, IMO-8400, in dermatomyositis","volume":"84","author":"Kim","year":"2021","journal-title":"Journal of the American Academy of Dermatology"},{"key":"10.1002\/14651858.CD015855-BIB0167|cit167","unstructured":"Trial of IMO-8400 in adult patients with dermatomyositis https:\/\/clinicaltrials.gov\/ct2\/show\/NCT02612857 2015"},{"key":"10.1002\/14651858.CD015855-BIB0168|cit168","unstructured":"A phase 1 study of MEDI7734 in type I interferon-mediated autoimmune diseases https:\/\/clinicaltrials.gov\/ct2\/show\/NCT02780674 2016"},{"key":"10.1002\/14651858.CD015855-BIB0169|cit169","unstructured":"Pirfenidone in progressive interstitial lung disease associated with clinically amyopathic dermatomyositis https:\/\/clinicaltrials.gov\/ct2\/show\/NCT02821689 2016"},{"key":"10.1002\/14651858.CD015855-BIB0170|cit170","first-page":"4443","article-title":"Randomized placebo-controlled trial to evaluate efficacy and safety of subcutaneous abatacept in adults with active idiopathic inflammatory myopathy: results of the 24-week double-blind and 28-week open-label periods","volume":"74","author":"Aggarwal","year":"2022","journal-title":"Arthritis and Rheumatology"},{"key":"10.1002\/14651858.CD015855-BIB0171|cit171","doi-asserted-by":"crossref","first-page":"711","DOI":"10.1136\/annrheumdis-2022-eular.7","article-title":"Randomized, double-blind, placebo-controlled trial to evaluate efficacy and safety of sc abatacept in adults with active idiopathic inflammatory myopathy","volume":"81","author":"Aggarwal","year":"2022","journal-title":"Annals of the Rheumatic Diseases"},{"key":"10.1002\/14651858.CD015855-BIB0172|cit172","unstructured":"A phase 3 trial to evaluate the effectiveness and safety of abatacept SC alongside standard treatment in comparison to standard treatment alone in improving disease activity in adults with active idiopathic inflammatory myopathy, a group of chronic autoimmune inflammatory diseases that affect skeletal muscle https:\/\/trialsearch.who.int\/Trial2.aspx?TrialID=EUCTR2016-002269-77-DE 2017"},{"key":"10.1002\/14651858.CD015855-BIB0173|cit173","unstructured":"Trial to evaluate the efficacy and safety of abatacept in combination with standard therapy compared to standard therapy alone in improving disease activity in adults with active idiopathic inflammatory myopathy https:\/\/trialsearch.who.int\/Trial2.aspx?TrialID=JPRN-JapicCTI-173670 2017"},{"key":"10.1002\/14651858.CD015855-BIB0174|cit174","unstructured":"Trial to evaluate the efficacy and safety of abatacept in combination with standard therapy compared to standard therapy alone in improving disease activity in adults with active idiopathic inflammatory myopathy https:\/\/clinicaltrials.gov\/ct2\/show\/NCT02971683 2017"},{"key":"10.1002\/14651858.CD015855-BIB0175|cit175","unstructured":"Phase IIa exploratory study to assess the safety and effect of IFNa-Kinoid (IFN-K) in adult patients with dermatomyositis https:\/\/trialsearch.who.int\/Trial2.aspx?TrialID=EUCTR2016-000137-52-DE 2016"},{"key":"10.1002\/14651858.CD015855-BIB0176|cit176","unstructured":"Study of IFN-K in dermatomyositis https:\/\/clinicaltrials.gov\/ct2\/show\/NCT02980198 2017"},{"key":"10.1002\/14651858.CD015855-BIB0177|cit177","unstructured":"Optimizing treatment on idiopathic inflammatory myopathies https:\/\/clinicaltrials.gov\/ct2\/show\/NCT03092180 2017"},{"key":"10.1002\/14651858.CD015855-BIB0178|cit178","unstructured":"A placebo-controlled study to evaluate the efficacy, safety and tolerability of PF-06823859 in adult subjects with dermatomyositis https:\/\/trialsearch.who.int\/Trial2.aspx?TrialID=EUCTR2020-004228-41-IT 2021"},{"key":"10.1002\/14651858.CD015855-BIB0179|cit179","unstructured":"A study in adults with moderate to severe dermatomyositis https:\/\/clinicaltrials.gov\/ct2\/show\/NCT03181893 2018"},{"key":"10.1002\/14651858.CD015855-BIB0180|cit180","unstructured":"Basiliximab treating interstitial pneumonia of CADM https:\/\/clinicaltrials.gov\/ct2\/show\/NCT03192657 2017"},{"key":"10.1002\/14651858.CD015855-BIB0181|cit181","unstructured":"Abatacept for the treatment of myositis-associated interstitial lung disease https:\/\/clinicaltrials.gov\/ct2\/show\/NCT03215927 2017"},{"key":"10.1002\/14651858.CD015855-BIB0182|cit182","unstructured":"A study to evaluate VIB7734 in participants with systemic lupus erythematosus (SLE), cutaneous lupus erythematosus (CLE), Sjogren's syndrome, systemic sclerosis, polymyositis, and dermatomyositis https:\/\/clinicaltrials.gov\/ct2\/show\/NCT03817424 2018"},{"key":"10.1002\/14651858.CD015855-BIB0183|cit183","unstructured":"A study of ustekinumab in participants with active polymyositis and dermatomyositis who have not adequately responded to one or more standard-of-care treatments https:\/\/trialsearch.who.int\/Trial2.aspx?TrialID=JPRN-JapicCTI-194822 2019"},{"key":"10.1002\/14651858.CD015855-BIB0184|cit184","unstructured":"A study of ustekinumab in participants with active polymyositis and dermatomyositis who have not adequately responded to one or more standard-of-care treatments https:\/\/clinicaltrials.gov\/ct2\/show\/NCT03981744 2019"},{"key":"10.1002\/14651858.CD015855-BIB0185|cit185","unstructured":"A study to evaluate the safety, tolerability, and efficacy of zilucoplan in subjects with immune-mediated necrotizing myopathy https:\/\/trialsearch.who.int\/Trial2.aspx?TrialID=EUCTR2019-001497-29-NL 2020"},{"key":"10.1002\/14651858.CD015855-BIB0186|cit186","unstructured":"Safety and efficacy study of zilucoplan in subjects with immune-mediated necrotizing myopathy https:\/\/clinicaltrials.gov\/ct2\/show\/NCT04025632 2019"},{"key":"10.1002\/14651858.CD015855-BIB0187|cit187","unstructured":"A study to evaluate the safety and efficacy of KZR-616 for the treatment of patients with active inflammations of the muscle and the skin (rheumatic disease) https:\/\/trialsearch.who.int\/Trial2.aspx?TrialID=EUCTR2019-002605-22-CZ 2019"},{"key":"10.1002\/14651858.CD015855-BIB0188|cit188","unstructured":"A study to evaluate the safety and efficacy of KZR-616 for the treatment of patients with active inflammations of the muscle and the skin (rheumatic disease) https:\/\/trialsearch.who.int\/Trial2.aspx?TrialID=EUCTR2019-002605-22-GB 2019"},{"key":"10.1002\/14651858.CD015855-BIB0189|cit189","unstructured":"A phase 2 study of KZR-616 to evaluate safety and efficacy in patients with active polymyositis or dermatomyositis https:\/\/clinicaltrials.gov\/ct2\/show\/NCT04033926 2020"},{"key":"10.1002\/14651858.CD015855-BIB0190|cit190","unstructured":"A trial of the drug baricitinib in the treatment of patients with muscle inflammatory conditions https:\/\/trialsearch.who.int\/Trial2.aspx?TrialID=EUCTR2019-003868-42-GB 2020"},{"key":"10.1002\/14651858.CD015855-BIB0191|cit191","unstructured":"A phase IIa trial of the oral JAK 1\/2 inhibitor, baricitinib, in the treatment of adult IIM https:\/\/clinicaltrials.gov\/ct2\/show\/NCT04208464 2020"},{"key":"10.1002\/14651858.CD015855-BIB0192|cit192","unstructured":"Low-dose interleukin-2 in combination with standard therapy on idiopathic inflammatory myopathy https:\/\/clinicaltrials.gov\/ct2\/show\/NCT04237987 2020"},{"key":"10.1002\/14651858.CD015855-BIB0193|cit193","unstructured":"Exercise, creatine and coenzyme Q10 for childhood myositis https:\/\/clinicaltrials.gov\/ct2\/show\/NCT04286178 2021"},{"key":"10.1002\/14651858.CD015855-BIB0194|cit194","unstructured":"Monotherapy IVIG Gamunex-C for HMG-CoA reductase auto-antibody positive necrotizing myopathy treatment (The MIGHT Trial) https:\/\/clinicaltrials.gov\/ct2\/show\/NCT04450654 2021"},{"key":"10.1002\/14651858.CD015855-BIB0195|cit195","unstructured":"Open-label extension to the phase 2 crossover study (PRESIDIO) evaluating KZR-616 in patients with PM and DM https:\/\/clinicaltrials.gov\/ct2\/show\/NCT04628936 2020"},{"key":"10.1002\/14651858.CD015855-BIB0196|cit196","unstructured":"Baricitinib in patients with relapsing or na\u00efve dermatomyositis https:\/\/clinicaltrials.gov\/ct2\/show\/NCT04972760 2021"},{"key":"10.1002\/14651858.CD015855-BIB0197|cit197","unstructured":"Evaluate the safety, tolerability and efficacy of PN-101 in patients with refractory polymyositis or dermatomyositis https:\/\/clinicaltrials.gov\/ct2\/show\/NCT04976140 2021"},{"key":"10.1002\/14651858.CD015855-BIB0198|cit198","unstructured":"A study to evaluate the safety, tolerability and efficacy of MHV370 in participants with Sjogren's Syndrome (SjS) or Mixed Connective Tissue Disease (MCTD) https:\/\/trialsearch.who.int\/Trial2.aspx?TrialID=EUCTR2020-004937-19-DE 2021"},{"key":"10.1002\/14651858.CD015855-BIB0199|cit199","first-page":"S165","article-title":"Design of a global phase 2\/3 randomized, placebo-controlled trial of ravulizumab in adult dermatomyositis","volume":"9","author":"Aggarwal","year":"2022","journal-title":"Journal of Neuromuscular Diseases"},{"key":"10.1002\/14651858.CD015855-BIB0200|cit200","doi-asserted-by":"crossref","first-page":"1750","DOI":"10.1136\/annrheumdis-2022-eular.1808","article-title":"Design of a global phase 2\/3 randomized, placebo-controlled trial evaluating the efficacy and safety of ravulizumab in adults with dermatomyositis","volume":"81","author":"Cavagna","year":"2022","journal-title":"Annals of the Rheumatic Diseases"},{"key":"10.1002\/14651858.CD015855-BIB0201|cit201","unstructured":"Ravulizumab versus placebo in adult participants with dermatomyositis https:\/\/trialsearch.who.int\/Trial2.aspx?TrialID=https:\/\/trialsearch.who.int\/Trial2.aspx?TrialID= 2021"},{"key":"10.1002\/14651858.CD015855-BIB0202|cit202","unstructured":"Ravulizumab versus placebo in adult participants with dermatomyositis https:\/\/clinicaltrials.gov\/ct2\/show\/NCT04999020 2021"},{"key":"10.1002\/14651858.CD015855-BIB0203|cit203","unstructured":"Ravulizumab versus placebo in adult participants with dermatomyositis https:\/\/trialsearch.who.int\/Trial2.aspx?TrialID=JPRN-jRCT2031210681 2022"},{"key":"10.1002\/14651858.CD015855-BIB0204|cit204","unstructured":"A study of nipocalimab in participants with active idiopathic inflammatory myopathies https:\/\/clinicaltrials.gov\/ct2\/show\/NCT05379634 2022"},{"key":"10.1002\/14651858.CD015855-BIB0205|cit205","unstructured":"A phase 3 study to investigate the efficacy and safety of brepocitinib in adults with dermatomyositis https:\/\/ClinicalTrials.gov\/show\/NCT05437263 2022"},{"key":"10.1002\/14651858.CD015855-BIB0206|cit206","unstructured":"Interleukin-2 on active dermatomyositis https:\/\/clinicaltrials.gov\/ct2\/show\/NCT05495321 2022"},{"key":"10.1002\/14651858.CD015855-BIB0207|cit207","unstructured":"Study of M5049 in DM and PM participants (NEPTUNIA) https:\/\/clinicaltrials.gov\/ct2\/show\/NCT05650567 2023"},{"key":"10.1002\/14651858.CD015855-BIB0208|cit208","unstructured":"A phase 2 proof of concept study to evaluate the efficacy and safety of daxdilimab in participants with dermatomyositis (DM) or anti-synthetase inflammatory myositis (ASIM) https:\/\/clinicaltrials.gov\/ct2\/show\/NCT05669014 2022"},{"key":"10.1002\/14651858.CD015855-BIB0209|cit209","unstructured":"A study evaluating the effects of GLPG3667 given as oral treatment for up to 24 weeks in adults with dermatomyositis https:\/\/clinicaltrials.gov\/ct2\/show\/NCT05695950 2023"},{"key":"10.1002\/14651858.CD015855-BIB0210|cit210","doi-asserted-by":"crossref","first-page":"108","DOI":"10.1186\/1471-2474-13-108","article-title":"Design of the muscles in motion study: a randomized controlled trial to evaluate the efficacy and feasibility of an individually tailored home-based exercise training program for children and adolescents with juvenile dermatomyositis","volume":"13","author":"Habers","year":"2012","journal-title":"BMC Musculoskeletal Disorders"},{"issue":"7","key":"10.1002\/14651858.CD015855-BIB0211|cit211","doi-asserted-by":"crossref","first-page":"1251","DOI":"10.1093\/rheumatology\/kew026","article-title":"Muscles in motion: a randomized controlled trial on the feasibility, safety and efficacy of an exercise training programme in children and adolescents with juvenile dermatomyositis","volume":"55","author":"Habers","year":"2016","journal-title":"Rheumatology"},{"key":"10.1002\/14651858.CD015855-BIB0212|cit212","unstructured":"A trial of rituximab compared to usual best care in patients with interstitial (inflammatory or scarring conditions) lung disease due to systemic autoimmune (connective tissue) diseases https:\/\/trialsearch.who.int\/Trial2.aspx?TrialID=EUCTR2012-003633-42-GB 2013"},{"key":"10.1002\/14651858.CD015855-BIB0213|cit213","unstructured":"Rituximab versus cyclophosphamide in connective tissue disease-ILD https:\/\/trialsearch.who.int\/Trial2.aspx?TrialID=ISRCTN16474148 2015"},{"key":"10.1002\/14651858.CD015855-BIB0214|cit214","first-page":"5","article-title":"Rituximab versus cyclophosphamide for the treatment of connective tissue disease associated interstitial lung disease (RECITAL): a subgroup analysis of a multi-centre randomised controlled trial","volume":"74","author":"Maher","year":"2022","journal-title":"Arthritis and Rheumatology"},{"issue":"1","key":"10.1002\/14651858.CD015855-BIB0215|cit215","first-page":"A4779","article-title":"Rituximab versus cyclophosphamide for the treatment of connective tissue disease associated interstitial lung disease (RECITAL): a multi-centre randomised controlled trial","volume":"205","author":"Maher","year":"2022","journal-title":"American Journal of Respiratory and Critical Care Medicine"},{"issue":"1","key":"10.1002\/14651858.CD015855-BIB0216|cit216","doi-asserted-by":"crossref","first-page":"45","DOI":"10.1016\/S2213-2600(22)00359-9","article-title":"Rituximab versus intravenous cyclophosphamide in patients with connective tissue disease-associated interstitial lung disease in the UK (RECITAL): a double-blind, double-dummy, randomised, controlled, phase 2b trial","volume":"11","author":"Maher","year":"2023","journal-title":"Lancet Respiratory Medicine"},{"key":"10.1002\/14651858.CD015855-BIB0217|cit217","unstructured":"Rituximab versus cyclophosphamide in connective tissue disease-ILD https:\/\/clinicaltrials.gov\/ct2\/show\/NCT01862926 2014"},{"issue":"1","key":"10.1002\/14651858.CD015855-BIB0218|cit218","doi-asserted-by":"crossref","first-page":"275","DOI":"10.1186\/s13063-017-2016-2","article-title":"Rituximab versus cyclophosphamide for the treatment of connective tissue disease associated interstitial lung disease (RECITAL): study protocol for a randomised controlled trial","volume":"18","author":"Saunders","year":"2017","journal-title":"Trials"},{"issue":"Suppl 1","key":"10.1002\/14651858.CD015855-BIB0219|cit219","first-page":"200 (Page 130 o","article-title":"Rituximab versus cyclophosphamide for the treatment of connective tissue disease associated interstitial lung disease (RECITAL): a randomised controlled trial","volume":"18","author":"Tsipouri","year":"2017","journal-title":"Trials"},{"issue":"3","key":"10.1002\/14651858.CD015855-BIB0220|cit220","doi-asserted-by":"crossref","first-page":"740","DOI":"10.1002\/art.38270","article-title":"Predictors of clinical improvement in rituximab-treated refractory adult and juvenile dermatomyositis and adult polymyositis","volume":"66","author":"Aggarwal","year":"2014","journal-title":"Arthritis and Rheumatology"},{"key":"10.1002\/14651858.CD015855-BIB0221|cit221","first-page":"S682","article-title":"Clinical and serologic predictors of response in rituximab-treated refractory adult and juvenile dermatomyositis (DM) and adult polymyositis (PM)-the RIM study","volume":"64","author":"Aggarwal","year":"2012","journal-title":"Arthritis and Rheumatism"},{"issue":"2","key":"10.1002\/14651858.CD015855-BIB0222|cit222","doi-asserted-by":"crossref","first-page":"247","DOI":"10.1093\/rheumatology\/kew396","article-title":"Cutaneous improvement in refractory adult and juvenile dermatomyositis after treatment with rituximab","volume":"56","author":"Aggarwal","year":"2017","journal-title":"Rheumatology"},{"key":"10.1002\/14651858.CD015855-BIB0223|cit223","first-page":"S325","article-title":"Effect of B cell depletion therapy with rituximab on myositis associated autoantibody levels in idiopathic inflammatory myopathy","volume":"64","author":"Aggarwal","year":"2012","journal-title":"Arthritis and Rheumatism"},{"issue":"6","key":"10.1002\/14651858.CD015855-BIB0224|cit224","doi-asserted-by":"crossref","first-page":"991","DOI":"10.1093\/rheumatology\/kev444","article-title":"Autoantibody levels in myositis patients correlate with clinical response during B cell depletion with rituximab","volume":"55","author":"Aggarwal","year":"2016","journal-title":"Rheumatology"},{"key":"10.1002\/14651858.CD015855-BIB0225|cit225","first-page":"S887","article-title":"Interferon-regulated chemokine and innate cytokine scores identify refractory myositis patients that respond better to rtuximab therapy","volume":"65","author":"De Padilla","year":"2013","journal-title":"Arthritis and Rheumatism"},{"issue":"5","key":"10.1002\/14651858.CD015855-BIB0226|cit226","first-page":"655","article-title":"Interferon-regulated chemokine score associated with improvement in disease activity in refractory myositis patients treated with rituximab","volume":"33","author":"Lopez De Padilla","year":"2015","journal-title":"Clinical and Experimental Rheumatology"},{"key":"10.1002\/14651858.CD015855-BIB0227|cit227","unstructured":"Rituximab for the treatment of refractory adult and juvenile dermatomyositis (DM) and adult polymyositis (PM) https:\/\/clinicaltrials.gov\/ct2\/show\/NCT00106184 2006"},{"issue":"2","key":"10.1002\/14651858.CD015855-BIB0228|cit228","doi-asserted-by":"crossref","first-page":"314","DOI":"10.1002\/art.37754","article-title":"Rituximab in the treatment of refractory adult and juvenile dermatomyositis and adult polymyositis: a randomized, placebo-phase trial","volume":"65","author":"Oddis","year":"2013","journal-title":"Arthritis and Rheumatism"},{"key":"10.1002\/14651858.CD015855-BIB0229|cit229","doi-asserted-by":"crossref","first-page":"257","DOI":"10.1186\/s12891-015-0710-3","article-title":"Biologic predictors of clinical improvement in rituximab-treated refractory myositis","volume":"16","author":"Reed","year":"2015","journal-title":"BMC Musculoskeletal Disorders"},{"key":"10.1002\/14651858.CD015855-BIB0230|cit230","doi-asserted-by":"crossref","first-page":"P96","DOI":"10.1186\/1546-0096-12-S1-P96","article-title":"Safety and efficacy of creatine supplementation in juvenile dermatomyositis: a randomized double-blind placebo-controlled cross-over trial","volume":"12","author":"Sallum","year":"2014","journal-title":"Pediatric Rheumatology"},{"issue":"1","key":"10.1002\/14651858.CD015855-BIB0231|cit231","doi-asserted-by":"crossref","first-page":"58","DOI":"10.1002\/mus.24681","article-title":"Efficacy and safety of creatine supplementation in juvenile dermatomyositis: a randomized, double-blind, placebo-controlled crossover trial","volume":"53","author":"Solis","year":"2016","journal-title":"Muscle and Nerve"},{"key":"10.1002\/14651858.CD015855-BIB0232|cit232","unstructured":"Tolerability and effectiveness of every-other-day atorvastatin dosing in patients with statin related muscle disease https:\/\/trialsearch.who.int\/Trial2.aspx?TrialID=SLCTR\/2015\/010 2015"},{"issue":"Suppl","key":"10.1002\/14651858.CD015855-BIB0233|cit233","first-page":"S489","article-title":"A pilot study of eculizumab in patients with dermatomyosilis","volume":"46","author":"Takada","year":"2002","journal-title":"Arthritis and Rheumatism"},{"issue":"11","key":"10.1002\/14651858.CD015855-BIB0234|cit234","doi-asserted-by":"crossref","first-page":"800","DOI":"10.1136\/ard.50.11.800","article-title":"A double blind, randomised, multicentre comparison of two doses of intravenous iloprost in the treatment of Raynaud's phenomenon secondary to connective tissue diseases","volume":"50","author":"Torley","year":"1991","journal-title":"Annals of the Rheumatic Diseases"},{"key":"10.1002\/14651858.CD015855-BIB0235|cit235","doi-asserted-by":"crossref","first-page":"A650","DOI":"10.1136\/annrheumdis-2013-eular.1931","article-title":"Real life experience suggests differential effects of rituximab on refractory dermatomyositis and polymyositis","volume":"72","author":"Unger","year":"2013","journal-title":"Annals of the Rheumatic Diseases"},{"issue":"5","key":"10.1002\/14651858.CD015855-BIB0236|cit236","doi-asserted-by":"crossref","first-page":"801","DOI":"10.1007\/s10067-012-1940-5","article-title":"Intravenous immunoglobulin therapy in adult patients with polymyositis\/dermatomyositis: a systematic literature review","volume":"31","author":"Wang","year":"2012","journal-title":"Clinical Rheumatology"},{"key":"10.1002\/14651858.CD015855-BIB0237|cit237","unstructured":"Cyclosporine A in the treatment of polymyositis \/dermatomyositis associated interstitial pulmonary disease: a prospective, opened, multicenter, randomized, controlled clinical study https:\/\/trialsearch.who.int\/Trial2.aspx?TrialID=ChiCTR1900025087 2019"},{"key":"10.1002\/14651858.CD015855-BIB0238|cit238","unstructured":"Effect of tacrolimus on dermatomyositis\/polymyositis https:\/\/trialsearch.who.int\/Trial2.aspx?TrialID=ChiCTR1900028143 2019"},{"key":"10.1002\/14651858.CD015855-BIB0239|cit239","unstructured":"Study of Treatment Approaches in Myositis (STRAIM): a prospective, multicenter, randomized and open label clinical study https:\/\/trialsearch.who.int\/Trial2.aspx?TrialID=https:\/\/trialsearch.who.int\/Trial2.aspx?TrialID= 2013"},{"key":"10.1002\/14651858.CD015855-BIB0240|cit240","unstructured":"Intravenousimmunoglobulin (IVIg) for the treatment of inflammatory myopathies https:\/\/ClinicalTrials.gov\/ct2\/show\/NCT00001261"},{"key":"10.1002\/14651858.CD015855-BIB0241|cit241","unstructured":"Efficacy and safety of pirfenidone in patient with dermatomyositis interstitial lung disease (Dm-ILD) https:\/\/clinicaltrials.gov\/ct2\/show\/NCT03857854"},{"key":"10.1002\/14651858.CD015855-BIB0242|cit242","unstructured":"A study to evaluate the efficacy, safety, and pharmacokinetics of IgPro20 in adults with dermatomyositis (DM) https:\/\/trialsearch.who.int\/Trial2.aspx?TrialID=EUCTR2018-003171-35-FR 2019"},{"key":"10.1002\/14651858.CD015855-BIB0243|cit243","unstructured":"A study to evaluate the efficacy, safety, and pharmacokinetics of IgPro20 in adults with dermatomyositis (DM) https:\/\/clinicaltrials.gov\/ct2\/show\/NCT04044690"},{"key":"10.1002\/14651858.CD015855-BIB0244|cit244","unstructured":"Phase III clinical trials in new onset juvenile dermatomyositis: steroids treatment versus steroids plus cyclosporine treatment versus steroids plus methotrexate treatment https:\/\/trialsearch.who.int\/Trial2.aspx?TrialID=NTR667 2006"},{"key":"10.1002\/14651858.CD015855-BIB0245|cit245","first-page":"588","article-title":"Efficacy and safety of the combined treatment with intravenous immunoglobulin and oral glucocorticoid in the elderly with dermatomyositis","volume":"27","author":"Tian","year":"2008","journal-title":"Chinese Journal of Geriatrics"},{"key":"10.1002\/14651858.CD015855-BIB0246|cit246","unstructured":"Efficacy and safety evaluation of short interval cyclophosphamide pulse infusion in patients with refractory idiopathic inflammatory myopathy: a double-blind, multicenter randomized clinical trial https:\/\/trialsearch.who.int\/Trial2.aspx?TrialID=ChiCTR2100049656 2021"},{"key":"10.1002\/14651858.CD015855-BIB0247|cit247","unstructured":"Efficacy and safety of corticosteroid monotherapy versus combination therapy of corticosteroid and tacrolimus for patients with anti-aminoacyl-tRNA synthetase antibody-positive polymyositis\/dermatomyositis-associated interstitial lung disease: a prospective randomized multicenter clinical trial https:\/\/trialsearch.who.int\/Trial2.aspx?TrialID=JPRN-UMIN000032022 2018"},{"key":"10.1002\/14651858.CD015855-BIB0248|cit248","unstructured":"Cyclophosphamide and azathioprine vs tacrolimus in antisynthetase syndrome-related interstitial lung disease https:\/\/clinicaltrials.gov\/ct2\/show\/NCT03770663"},{"key":"10.1002\/14651858.CD015855-BIB0249|cit249","unstructured":"Efficacy and safety of triple therapy in patients with Anti-MDA5 antibody-positive dermatomyositis https:\/\/clinicaltrials.gov\/ct2\/show\/NCT05375435"},{"key":"10.1002\/14651858.CD015855-BIB0250|cit250","unstructured":"Efficacy and safety of pirfenidone in CTD-ILD https:\/\/clinicaltrials.gov\/ct2\/show\/NCT05505409"},{"key":"10.1002\/14651858.CD015855-BIB0251|cit251","unstructured":"A study to investigate the efficacy and safety of efgartigimod PH20 SC in adult participants with active idiopathic inflammatory myopathy https:\/\/clinicaltrials.gov\/ct2\/show\/NCT05523167"},{"key":"10.1002\/14651858.CD015855-BIB0252|cit252","unstructured":"Intravenous immunoglobulin and prednisone vs. prednisone in newly diagnosed myositis: a double blind randomized clinical trial https:\/\/trialsearch.who.int\/Trial2.aspx?TrialID=EUCTR2020-001710-37-NL 2021"},{"key":"10.1002\/14651858.CD015855-BIB0253|cit253","first-page":"S264","article-title":"Design of 'Time Is Muscle': RCT on IVIg add-on to prednisone in newly diagnosed myositis","volume":"9","author":"Kamperman","year":"2022","journal-title":"Journal of Neuromuscular Diseases"},{"key":"10.1002\/14651858.CD015855-BIB0254|cit254","unstructured":"IVIG in myositis: Time is Muscle (TIM) https:\/\/trialsearch.who.int\/Trial2.aspx?TrialID=NL9722 2021"},{"key":"10.1002\/14651858.CD015855-BIB0255|cit255","doi-asserted-by":"publisher","first-page":"165","DOI":"10.1016\/j.jclinepi.2021.02.002","article-title":"No limitations to language, date, publication type, and publication status in search step of systematic reviews","volume":"133","author":"Aali","year":"2021","journal-title":"Journal of Clinical Epidemiology"},{"issue":"2","key":"10.1002\/14651858.CD015855-BIB0256|cit256","doi-asserted-by":"crossref","first-page":"141","DOI":"10.1001\/archneur.1996.00550020045014","article-title":"The Amyotrophic Lateral Sclerosis Functional Rating Scale. Assessment of activities of daily living in patients with amyotrophic lateral sclerosis. The ALS CNTF treatment study (ACTS) phase I-II Study Group","volume":"53","year":"1996","journal-title":"Archives of Neurology"},{"issue":"5","key":"10.1002\/14651858.CD015855-BIB0257|cit257","doi-asserted-by":"crossref","first-page":"792","DOI":"10.1136\/annrheumdis-2017-211400","article-title":"2016 American College of Rheumatology\/European League Against Rheumatism criteria for minimal, moderate, and major clinical response in adult dermatomyositis and polymyositis: An International Myositis Assessment and Clinical Studies Group\/Paediatric Rheumatology International Trials Organisation Collaborative Initiative","volume":"76","author":"Aggarwal","year":"2017","journal-title":"Annals of the Rheumatic Diseases"},{"issue":"5","key":"10.1002\/14651858.CD015855-BIB0258|cit258","doi-asserted-by":"crossref","first-page":"262","DOI":"10.1159\/000110327","article-title":"Epidemiology of neuromuscular diseases, including the postpolio sequelae, in a Swedish county","volume":"12","author":"Ahlstrom","year":"1993","journal-title":"Neuroepidemiology"},{"issue":"4","key":"10.1002\/14651858.CD015855-BIB0259|cit259","doi-asserted-by":"crossref","first-page":"949","DOI":"10.1111\/bjd.18223","article-title":"Evaluating important change in cutaneous disease activity as an efficacy measure for clinical trials in dermatomyositis","volume":"182","author":"Ahmed","year":"2020","journal-title":"British Journal of Dermatology"},{"issue":"1","key":"10.1002\/14651858.CD015855-BIB0260|cit260","doi-asserted-by":"crossref","first-page":"87","DOI":"10.1016\/j.nmd.2017.09.016","article-title":"224th ENMC International Workshop: Clinico-sero-pathological classification of immune-mediated necrotizing myopathies Zandvoort, The Netherlands, 14\u201316 October 2016","volume":"28","author":"Allenbach","year":"2018","journal-title":"Neuromuscular Disorders"},{"issue":"1","key":"10.1002\/14651858.CD015855-BIB0261|cit261","doi-asserted-by":"crossref","first-page":"87","DOI":"10.1016\/j.nmd.2017.09.016","article-title":"224th ENMC International Workshop: Clinico-sero-pathological classification of immune-mediated necrotizing myopathies Zandvoort, The Netherlands, 14\u201316 October 2016","volume":"28","author":"Allenbach","year":"2017","journal-title":"Neuromuscular Disorders"},{"issue":"2","key":"10.1002\/14651858.CD015855-BIB0262|cit262","doi-asserted-by":"crossref","first-page":"113","DOI":"10.1016\/j.autrev.2018.07.013","article-title":"Treatment of idiopathic inflammatory myositis associated interstitial lung disease: a systematic review and meta-analysis","volume":"18","author":"Barba","year":"2019","journal-title":"Autoimmunity Reviews"},{"issue":"3","key":"10.1002\/14651858.CD015855-BIB0263|cit263","doi-asserted-by":"crossref","first-page":"245","DOI":"10.1038\/sj.bjp.0706736","article-title":"How corticosteroids control inflammation: Quintiles Prize Lecture 2005","volume":"148","author":"Barnes","year":"2006","journal-title":"British Journal of Pharmacology"},{"key":"10.1002\/14651858.CD015855-BIB0264|cit264","doi-asserted-by":"publisher","first-page":"611\u201324","DOI":"10.1007\/s00401-015-1384-5","article-title":"Amyloid deposits and inflammatory infiltrates in sporadic inclusion body myositis: the inflammatory egg comes before the degenerative chicken","volume":"129","author":"Benveniste","year":"2015","journal-title":"Acta Neuropathologica"},{"key":"10.1002\/14651858.CD015855-BIB0265|cit265","doi-asserted-by":"crossref","first-page":"48","DOI":"10.1016\/j.jaut.2019.04.001","article-title":"Frequency, mutual exclusivity and clinical associations of myositis autoantibodies in a combined European cohort of idiopathic inflammatory myopathy patients","volume":"101","author":"Betteridge","year":"2019","journal-title":"Journal of Autoimmunity"},{"issue":"7","key":"10.1002\/14651858.CD015855-BIB0266|cit266","doi-asserted-by":"crossref","first-page":"344","DOI":"10.1056\/NEJM197502132920706","article-title":"Polymyositis and dermatomyositis (first of two parts)","volume":"292","author":"Bohan","year":"1975","journal-title":"New England Journal of Medicine"},{"issue":"8","key":"10.1002\/14651858.CD015855-BIB0267|cit267","doi-asserted-by":"crossref","first-page":"403","DOI":"10.1056\/NEJM197502202920807","article-title":"Polymyositis and dermatomyositis (second of two parts)","volume":"292","author":"Bohan","year":"1975","journal-title":"New England Journal of Medicine"},{"issue":"3","key":"10.1002\/14651858.CD015855-BIB0268|cit268","doi-asserted-by":"crossref","first-page":"751","DOI":"10.3390\/nu13030751","article-title":"The role of creatine in the development and activation of immune responses","volume":"13","author":"Bredahl","year":"2021","journal-title":"Nutrients"},{"key":"10.1002\/14651858.CD015855-BIB0269|cit269","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1186\/1477-7525-1-20","article-title":"The Stanford health assessment questionnaire: dimensions and practical applications","volume":"1","author":"Bruce","year":"2003","journal-title":"Health and quality of life outcomes"},{"issue":"1","key":"10.1002\/14651858.CD015855-BIB0270|cit270","first-page":"167","article-title":"The Stanford Health Assessment Questionnaire: a review of its history, issues, progress, and documentation","volume":"30","author":"Bruce","year":"2003","journal-title":"Journal of Rheumatology"},{"issue":"1-2","key":"10.1002\/14651858.CD015855-BIB0271|cit271","doi-asserted-by":"crossref","first-page":"178","DOI":"10.3109\/17482960903093710","article-title":"Clinical significance in the change of decline in ALSFRS-R","volume":"11","author":"Castrillo-Viguera","year":"2010","journal-title":"Amyotrophic Lateral Sclerosis"},{"issue":"4","key":"10.1002\/14651858.CD015855-BIB0272|cit272","doi-asserted-by":"publisher","first-page":"694","DOI":"10.1002\/art.22687","article-title":"Creatine supplements in patients with idiopathic inflammatory myopathies who are clinically weak after conventional pharmacologic treatment: six-month, double-blind, randomized, placebo-controlled trial","volume":"57","author":"Chung","year":"2007","journal-title":"Arthritis & Rheumatology"},{"key":"10.1002\/14651858.CD015855-BIB0273|cit273","first-page":"494","article-title":"Polyarticular disability: a functional assessment","volume":"58","author":"Convery","year":"1977","journal-title":"Archives of Physical Medicine and Rehabilation"},{"key":"10.1002\/14651858.CD015855-BIB0274|cit274","unstructured":"Covidence Veritas Health Innovation 2023"},{"key":"10.1002\/14651858.CD015855-BIB0275|cit275","doi-asserted-by":"crossref","first-page":"145","DOI":"10.1038\/s41584-020-0373-9","article-title":"Methotrexate and its mechanisms of action in inflammatory arthritis","volume":"16","author":"Cronstein","year":"2020","journal-title":"Nature Reviews Rheumatology"},{"issue":"21","key":"10.1002\/14651858.CD015855-BIB0276|cit276","doi-asserted-by":"crossref","first-page":"1487","DOI":"10.1056\/NEJM199111213252107","article-title":"Polymyositis, dermatomyositis, and inclusion-body myositis","volume":"325","author":"Dalakas","year":"1991","journal-title":"New England Journal of Medicine"},{"issue":"5","key":"10.1002\/14651858.CD015855-BIB0277|cit277","doi-asserted-by":"crossref","first-page":"569","DOI":"10.1136\/jnnp.70.5.569","article-title":"Progress in inflammatory myopathies: good but not good enough","volume":"70","author":"Dalakas","year":"2001","journal-title":"Journal of Neurology, Neurosurgery and Psychiatry"},{"key":"10.1002\/14651858.CD015855-BIB0278|cit278","unstructured":"Deeks JJ Higgins JP Altman DG Chapter 10: Analysing data and undertaking meta-analyses. In: Higgins JP, Thomas J, Chandler J, Cumpston M, Li T, Page MJ, Welch VA, editor(s). Cochrane Handbook for Systematic Reviews of Interventions version 6.2 (updated February 2021). Cochrane, 2021 Available from training.cochrane.org\/handbook"},{"key":"10.1002\/14651858.CD015855-BIB0279|cit279","unstructured":"RevMan calculator Drahota A Beller E Available from: https:\/\/training.cochrane.org\/resource\/revman-calculator"},{"issue":"2","key":"10.1002\/14651858.CD015855-BIB0280|cit280","first-page":"326","article-title":"Measuring disability in juvenile dermatomyositis: validity of the Childhood Health Assessment Questionnaire","volume":"22","author":"Feldman","year":"1995","journal-title":"Journal of Rheumatology"},{"issue":"2","key":"10.1002\/14651858.CD015855-BIB0281|cit281","doi-asserted-by":"crossref","first-page":"102997","DOI":"10.1016\/j.autrev.2021.102997","article-title":"Efficacy and safety of intravenous and subcutaneous immunoglobulin therapy in idiopathic inflammatory myopathy: a systematic review and meta-analysis","volume":"21","author":"Goswami","year":"2022","journal-title":"Autoimmunity Reviews"},{"key":"10.1002\/14651858.CD015855-BIB0282|cit282","unstructured":"GRADEpro GDT: GRADEpro Guideline Development Tool McMaster University and Evidence Prime 2022"},{"key":"10.1002\/14651858.CD015855-BIB0283|cit283","unstructured":"Higgins JP Altman DG Sterne JA Chapter 8: Assessing risk of bias in included studies. In: Higgins JP, Green S, editor(s). Cochrane Handbook for Systematic Reviews of Interventions Version 5.1.0 (updated March 2011). The Cochrane Collaboration, 2011 Available from https:\/\/www.cochrane.org\/authors\/handbooks-and-manuals\/handbook\/archive\/v5.1.0"},{"key":"10.1002\/14651858.CD015855-BIB0284|cit284","unstructured":"Higgins JP Li T Deeks JJ Chapter 6: Choosing effect measures and computing estimates of effect. In: Higgins JP, Thomas J, Chandler J, Cumpston M, Li T, Page MJ, Welch VA, editor(s). Cochrane Handbook for Systematic Reviews of Interventions version 6.2 (updated February 2021). Cochrane, 2021 Available from https:\/\/www.cochrane.org\/handbook"},{"key":"10.1002\/14651858.CD015855-BIB0285|cit285","unstructured":"Higgins JP Eldridge S Li T Chapter 23: Including variants on randomized trials. In: Higgins JP, Thomas J, Chandler J, Cumpston M, Li T, Page MJ, Welch VA, editor(s). Cochrane Handbook for Systematic Reviews of Interventions version 6.2 (updated February 2021). Cochrane, 2021 Available from https:\/\/www.cochrane.org\/handbook"},{"issue":"4","key":"10.1002\/14651858.CD015855-BIB0286|cit286","doi-asserted-by":"crossref","first-page":"488","DOI":"10.1016\/j.semarthrit.2016.07.014","article-title":"Critical review of the role of intravenous immunoglobulins in idiopathic inflammatory myopathies","volume":"46","author":"Anh-Tu Hoa","year":"2017","journal-title":"Seminars in Arthritis and Rheumatism"},{"issue":"5","key":"10.1002\/14651858.CD015855-BIB0287|cit287","doi-asserted-by":"crossref","first-page":"337","DOI":"10.1016\/j.nmd.2004.02.006","article-title":"119th ENMC international workshop: trial design in adult idiopathic inflammatory myopathies, with the exception of inclusion body myositis, 10-12 October 2003, Naarden, The Netherlands","volume":"14","author":"Hoogendijk","year":"2004","journal-title":"Neuromuscular Disorders"},{"issue":"5","key":"10.1002\/14651858.CD015855-BIB0288|cit288","first-page":"1106","article-title":"Validation of the Childhood Health Assessment Questionnaire in the juvenile idiopathic myopathies","volume":"28","author":"Huber","year":"2001","journal-title":"Journal of Rheumatology"},{"issue":"1","key":"10.1002\/14651858.CD015855-BIB0289|cit289","doi-asserted-by":"crossref","first-page":"P280","DOI":"10.1016\/j.jaci.2022.09.010","article-title":"Azathioprine therapy induces selective NK cell depletion and IFN-\u03b3 deficiency predisposing to herpesvirus reactivation","volume":"151","author":"Ingelfinger","year":"2023","journal-title":"Journal of Allergy and Clinical Immunology"},{"issue":"8","key":"10.1002\/14651858.CD015855-BIB0290|cit290","doi-asserted-by":"crossref","first-page":"4301","DOI":"10.3390\/ijms23084301","article-title":"Pathophysiological mechanisms and treatment of dermatomyositis and immune mediated necrotizing myopathies: a focused review","volume":"23","author":"Kamperman","year":"2022","journal-title":"International Journal of Molecular Sciences"},{"issue":"11","key":"10.1002\/14651858.CD015855-BIB0291|cit291","doi-asserted-by":"crossref","first-page":"695","DOI":"10.1038\/s41584-023-01033-0","article-title":"Epidemiology of the idiopathic inflammatory myopathies","volume":"19","author":"Khoo","year":"2023","journal-title":"Nature Reviews Rheumatology"},{"issue":"12","key":"10.1002\/14651858.CD015855-BIB0292|cit292","doi-asserted-by":"crossref","first-page":"2089","DOI":"10.1136\/ard.2011.153718","article-title":"Efficacy of intravenous Ig therapy in juvenile dermatomyositis","volume":"70","author":"Lam","year":"2011","journal-title":"Annals of the Rheumatic Diseases"},{"issue":"8","key":"10.1002\/14651858.CD015855-BIB0293|cit293","doi-asserted-by":"crossref","first-page":"e199","DOI":"10.1097\/TXD.0000000000000715","article-title":"The effects of tacrolimus on T-cell proliferation are short-lived: a pilot analysis of immune function testing","volume":"3","author":"Laskin","year":"2017","journal-title":"Transplant Direct"},{"issue":"6","key":"10.1002\/14651858.CD015855-BIB0294|cit294","doi-asserted-by":"crossref","first-page":"537","DOI":"10.1097\/BOR.0000000000000837","article-title":"Polymyositis: does it really exist as a distinct clinical subset?","volume":"33","author":"Leclair","year":"2021","journal-title":"Current Opinion in Rheumatology"},{"issue":"4","key":"10.1002\/14651858.CD015855-BIB0295|cit295","doi-asserted-by":"publisher","first-page":"1784","DOI":"10.1093\/rheumatology\/keaa459","article-title":"Intravenous immunoglobulins as first-line treatment in idiopathic inflammatory myopathies: a pilot study","volume":"60","author":"Lim","year":"2020","journal-title":"Rheumatology"},{"issue":"7","key":"10.1002\/14651858.CD015855-BIB0296|cit296","doi-asserted-by":"publisher","first-page":"3398\u2013403","DOI":"10.1093\/rheumatology\/keaa801","article-title":"Polymyositis: is there anything left? A retrospective diagnostic review from a tertiary myositis centre","volume":"60","author":"Loarce-Martos","year":"2020","journal-title":"Rheumatology"},{"issue":"7","key":"10.1002\/14651858.CD015855-BIB0297|cit297","doi-asserted-by":"crossref","first-page":"3398","DOI":"10.1093\/rheumatology\/keaa801","article-title":"Polymyositis: is there anything left? A retrospective diagnostic review from a tertiary myositis centre","volume":"60","author":"Loarce-Martos","year":"2021","journal-title":"Rheumatology"},{"issue":"12","key":"10.1002\/14651858.CD015855-BIB0298|cit298","doi-asserted-by":"crossref","first-page":"2271","DOI":"10.1002\/art.40320","article-title":"2017 European League Against Rheumatism\/American College of Rheumatology Classification Criteria for Adult and Juvenile Idiopathic Inflammatory Myopathies and Their Major Subgroups","volume":"69","author":"Lundberg","year":"2017","journal-title":"Arthritis & Rheumatology"},{"issue":"17","key":"10.1002\/14651858.CD015855-BIB0299|cit299","doi-asserted-by":"crossref","first-page":"1680","DOI":"10.1056\/NEJMc1506163","article-title":"Intravenous immune globulin for statin-triggered autoimmune myopathy","volume":"373","author":"Mammen","year":"2015","journal-title":"New England Journal of Medicine"},{"issue":"1","key":"10.1002\/14651858.CD015855-BIB0300|cit300","doi-asserted-by":"crossref","first-page":"70","DOI":"10.1016\/j.nmd.2019.10.005","article-title":"239th ENMC international workshop: classification of dermatomyositis, Amsterdam, the Netherlands, 14\u201316 December 2018","volume":"30","author":"Mammen","year":"2020","journal-title":"Neuromuscular Disorders"},{"issue":"12","key":"10.1002\/14651858.CD015855-BIB0301|cit301","doi-asserted-by":"crossref","first-page":"1528","DOI":"10.1001\/jamaneurol.2018.2598","article-title":"Development of a new classification system for idiopathic inflammatory myopathies based on clinical manifestations and myositis-specific autoantibodies","volume":"75","author":"Mariampillai","year":"2018","journal-title":"JAMA Neurology"},{"key":"10.1002\/14651858.CD015855-BIB0302|cit302","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1186\/ar4332","article-title":"Functional outcome and prognostic factors in anti-Jo1 patients with antisynthetase syndrome","volume":"15","author":"Marie","year":"2013","journal-title":"Arthritis Research & Therapy"},{"issue":"2-3","key":"10.1002\/14651858.CD015855-BIB0303|cit303","doi-asserted-by":"crossref","first-page":"119","DOI":"10.1016\/S0162-3109(00)00192-2","article-title":"Mechanisms of action of cyclosporine","volume":"47","author":"Matsuda","year":"2000","journal-title":"Immunopharmacology"},{"key":"10.1002\/14651858.CD015855-BIB0304|cit304","unstructured":"McKenzie JE Brennan SE Chapter 12: Synthesizing and presenting findings using other methods. In: Higgins JP, Thomas J, Chandler J, Cumpston M, Li T, Page MJ, Welch VA, editor(s). Cochrane Handbook for Systematic Reviews of Interventions version 6.2 (updated February 2021). Cochrane, 2021 Available from https:\/\/www.cochrane.org\/handbook"},{"issue":"1","key":"10.1002\/14651858.CD015855-BIB0305|cit305","doi-asserted-by":"crossref","first-page":"106","DOI":"10.3899\/jrheum.180353","article-title":"Perceptions of patients, caregivers, and healthcare providers of idiopathic inflammatory myopathies: an international OMERACT study","volume":"46","author":"Mecoli","year":"2019","journal-title":"Journal of Rheumatology"},{"issue":"1","key":"10.1002\/14651858.CD015855-BIB0306|cit306","doi-asserted-by":"crossref","first-page":"50","DOI":"10.1093\/rheumatology\/keu289","article-title":"Incidence and prevalence of inflammatory myopathies: a systematic review","volume":"54","author":"Meyer","year":"2015","journal-title":"Rheumatology"},{"issue":"1","key":"10.1002\/14651858.CD015855-BIB0307|cit307","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1186\/s13075-019-2093-6","article-title":"Statin-induced anti-HMGCR myopathy: successful therapeutic strategies for corticosteroid-free remission in 55 patients","volume":"22","author":"Meyer","year":"2020","journal-title":"Arthritis Research & Therapy"},{"issue":"9","key":"10.1002\/14651858.CD015855-BIB0308|cit308","doi-asserted-by":"crossref","first-page":"2607","DOI":"10.1002\/art.21291","article-title":"International consensus guidelines for trials of therapies in the idiopathic inflammatory myopathies","volume":"52","author":"Oddis","year":"2005","journal-title":"Arthritis and Rheumatism"},{"key":"10.1002\/14651858.CD015855-BIB0309|cit309","doi-asserted-by":"publisher","first-page":"n71","DOI":"10.1136\/bmj.n71","article-title":"The PRISMA 2020 statement: an updated guideline for reporting systematic reviews","volume":"372","author":"Page","year":"2021","journal-title":"BMJ"},{"key":"10.1002\/14651858.CD015855-BIB0310|cit310","unstructured":"Page MJ Higgins JP Chapter 13: Assessing risk of bias due to missing results in a synthesis. In: Higgins JP, Thomas J, Chandler J, Cumpston M, Li T, Page MJ, Welch VA, editor(s). Cochrane Handbook for Systematic Reviews of Interventions version 6.2 (updated February 2021). Cochrane, 2021 Available from https:\/\/www.cochrane.org\/handbook"},{"key":"10.1002\/14651858.CD015855-BIB0311|cit311","doi-asserted-by":"crossref","first-page":"S10","DOI":"10.1097\/01.MIB.0000195386.19268.b3","article-title":"Developments in the apheresis procedure for the treatment of inflammatory bowel disease","volume":"12","author":"Pineda","year":"2006","journal-title":"Inflammatory Bowel Diseases"},{"issue":"1","key":"10.1002\/14651858.CD015855-BIB0312|cit312","doi-asserted-by":"publisher","first-page":"83","DOI":"10.1093\/rheumatology\/keh404","article-title":"Functional outcome and quality of life in adult patients with idiopathic inflammatory myositis","volume":"44","author":"Ponyi","year":"2005","journal-title":"Rheumatology"},{"issue":"8","key":"10.1002\/14651858.CD015855-BIB0313|cit313","doi-asserted-by":"publisher","DOI":"10.1002\/14651858.CD015854","article-title":"Targeted immunosuppressive and immunomodulatory therapies for idiopathic inflammatory myopathies","author":"Raaphorst","year":"2025","journal-title":"Cochrane Database of Systematic Reviews"},{"issue":"3","key":"10.1002\/14651858.CD015855-BIB0314|cit314","doi-asserted-by":"publisher","first-page":"e96","DOI":"10.1212\/NXI.0000000000000096","article-title":"Clinical course and treatment of anti-HMGCR antibody\u2013associated necrotizing autoimmune myopathy","volume":"2","author":"Ramanathan","year":"2015","journal-title":"Neurology-Neuroimmunology & Neuroinflammation"},{"key":"10.1002\/14651858.CD015855-BIB0315|cit315","unstructured":"Review Manager (RevMan) The Cochrane Collaboration 2020"},{"key":"10.1002\/14651858.CD015855-BIB0316|cit316","unstructured":"Review Manager Web (RevMan Web) The Cochrane Collaboration"},{"issue":"3","key":"10.1002\/14651858.CD015855-BIB0317|cit317","first-page":"603","article-title":"Defining clinical improvement in adult and juvenile myositis","volume":"30","author":"Rider","year":"2003","journal-title":"Journal of Rheumatology"},{"issue":"7","key":"10.1002\/14651858.CD015855-BIB0318|cit318","doi-asserted-by":"crossref","first-page":"2281","DOI":"10.1002\/art.20349","article-title":"International consensus on preliminary definitions of improvement in adult and juvenile myositis","volume":"50","author":"Rider","year":"2004","journal-title":"Arthritis and Rheumatism"},{"issue":"4","key":"10.1002\/14651858.CD015855-BIB0319|cit319","doi-asserted-by":"publisher","first-page":"465","DOI":"10.1002\/acr.20035","article-title":"Validation of manual muscle testing and a subset of eight muscles for adult and juvenile idiopathic inflammatory myopathies","volume":"62","author":"Rider","year":"2010","journal-title":"Arthritis Care & Research"},{"key":"10.1002\/14651858.CD015855-BIB0320|cit320","first-page":"S118","article-title":"Measures of adult and juvenile dermatomyositis, polymyositis, and inclusion body myositis: Physician and Patient\/Parent Global Activity, Manual Muscle Testing (MMT), Health Assessment Questionnaire (HAQ)\/Childhood Health Assessment Questionnaire (C-HAQ), Childhood Myositis Assessment Scale (CMAS), Myositis Disease Activity Assessment Tool (MDAAT), Disease Activity Score (DAS), Short Form 36 (SF-36), Child Health Questionnaire (CHQ), physician global damage, Myositis Damage Index (MDI), Quantitative Muscle Testing (QMT), Myositis Functional Index-2 (FI-2), Myositis Activities Profile (MAP), Inclusion Body Myositis Functional Rating Scale (IBMFRS), Cutaneous Dermatomyositis Disease Area and Severity Index (CDASI), Cutaneous Assessment Tool (CAT), Dermatomyositis Skin Severity Index (DSSI), Skindex, and Dermatology Life Quality Index (DLQI)","volume":"63 No. S11","author":"Rider","year":"2011","journal-title":"Arthritis Care & Research"},{"issue":"4","key":"10.1002\/14651858.CD015855-BIB0321|cit321","doi-asserted-by":"crossref","first-page":"284","DOI":"10.1136\/practneurol-2017-001742","article-title":"Autoantibody testing in idiopathic inflammatory myopathies","volume":"19","author":"Rietveld","year":"2019","journal-title":"Practical Neurology"},{"issue":"6","key":"10.1002\/14651858.CD015855-BIB0322|cit322","doi-asserted-by":"publisher","DOI":"10.1002\/14651858.CD001555.pub5","article-title":"Treatment for inclusion body myositis","author":"Rose","year":"2015","journal-title":"Cochrane Database of Systematic Reviews"},{"issue":"2","key":"10.1002\/14651858.CD015855-BIB0323|cit323","doi-asserted-by":"crossref","first-page":"109","DOI":"10.3233\/JND-180308","article-title":"Current classification and management of inflammatory myopathies","volume":"5","author":"Schmidt","year":"2018","journal-title":"Journal of Neuromuscular Diseases"},{"key":"10.1002\/14651858.CD015855-BIB0324|cit324","unstructured":"Sch\u00fcnemann HJ Vist GE Higgins JP Santesso N Deeks JJ Glasziou P Akl EA Guyatt GH Chapter 15: Interpreting results and drawing conclusions. In: Higgins JP, Thomas J, Chandler J, Cumpston M, Li T, Page MJ, Welch VA, editor(s). Cochrane Handbook for Systematic Reviews of Interventions version 6.2 (updated February 2021). Cochrane, 2021 Available from https:\/\/www.cochrane.org\/handbook"},{"issue":"5","key":"10.1002\/14651858.CD015855-BIB0325|cit325","doi-asserted-by":"crossref","first-page":"590","DOI":"10.1097\/WCO.0000000000000855","article-title":"Where are we moving in the classification of idiopathic inflammatory myopathies?","volume":"33","author":"Tanboon","year":"2020","journal-title":"Current Opinion in Neurology"},{"issue":"4","key":"10.1002\/14651858.CD015855-BIB0326|cit326","doi-asserted-by":"crossref","first-page":"1086","DOI":"10.1111\/bjd.15596","article-title":"Evaluation of the reliability of the Cutaneous Dermatomyositis Disease Area and Severity Index and the Cutaneous Assessment Tool-Binary Method in juvenile dermatomyositis among paediatric dermatologists, rheumatologists and neurologists","volume":"177","author":"Tiao","year":"2017","journal-title":"British Journal of Dermatology"},{"issue":"2","key":"10.1002\/14651858.CD015855-BIB0327|cit327","doi-asserted-by":"crossref","first-page":"156","DOI":"10.1034\/j.1600-6143.2003.00011.x","article-title":"Pooled human gammaglobulin modulates surface molecule expression and induces apoptosis in human B cells","volume":"3","author":"Toyoda","year":"2003","journal-title":"American Journal of Transplantation"},{"issue":"3","key":"10.1002\/14651858.CD015855-BIB0328|cit328","doi-asserted-by":"crossref","first-page":"316","DOI":"10.1212\/WNL.61.3.316","article-title":"Polymyositis: an overdiagnosed entity","volume":"61","author":"Meulen","year":"2003","journal-title":"Neurology"},{"issue":"1","key":"10.1002\/14651858.CD015855-BIB0329|cit329","doi-asserted-by":"crossref","first-page":"7","DOI":"10.1182\/asheducation.V2012.1.7.3797920","article-title":"Plasma exchange: concepts, mechanisms, and an overview of the American Society for Apheresis guidelines","volume":"2012","author":"Winters","year":"2012","journal-title":"Hematology. American Society of Hematology. Education Program"},{"issue":"3","key":"10.1002\/14651858.CD015855-BIB0330|cit330","doi-asserted-by":"crossref","first-page":"533","DOI":"10.1093\/mr\/roac057","article-title":"The therapeutic efficacy and safety of intravenous immunoglobulin in dermatomyositis and polymyositis: a systematic review and meta-analysis","volume":"33","author":"Xiong","year":"2023","journal-title":"Modern Rheumatology"},{"issue":"3","key":"10.1002\/14651858.CD015855-BIB0331|cit331","doi-asserted-by":"crossref","first-page":"669","DOI":"10.1111\/j.1365-2133.2009.09521.x","article-title":"Modification of the cutaneous dermatomyositis disease area and severity index, an outcome instrument","volume":"162","author":"Yassaee","year":"2010","journal-title":"British Journal of Dermatology"},{"issue":"2","key":"10.1002\/14651858.CD015855-BIB0332|cit332","doi-asserted-by":"publisher","DOI":"10.1002\/14651858.CD003643","article-title":"Immunosuppressant and immunomodulatory treatment for dermatomyositis and polymyositis","author":"Choy","year":"2005","journal-title":"Cochrane Database of Systematic Reviews"},{"issue":"3","key":"10.1002\/14651858.CD015855-BIB0333|cit333","doi-asserted-by":"publisher","DOI":"10.1002\/14651858.CD003643.pub2","article-title":"Immunosuppressant and immunomodulatory treatment for dermatomyositis and polymyositis","author":"Choy","year":"2005","journal-title":"Cochrane Database of Systematic Reviews"},{"issue":"4","key":"10.1002\/14651858.CD015855-BIB0334|cit334","doi-asserted-by":"publisher","DOI":"10.1002\/14651858.CD003643.pub3","article-title":"Immunosuppressant and immunomodulatory treatment for dermatomyositis and polymyositis","author":"Choy","year":"2009","journal-title":"Cochrane Database of Systematic Reviews"},{"issue":"8","key":"10.1002\/14651858.CD015855-BIB0335|cit335","doi-asserted-by":"publisher","DOI":"10.1002\/14651858.CD003643.pub4","article-title":"Immunosuppressant and immunomodulatory treatment for dermatomyositis and polymyositis","author":"Gordon","year":"2012","journal-title":"Cochrane Database of Systematic Reviews"},{"issue":"1","key":"10.1002\/14651858.CD015855-BIB0336|cit336","doi-asserted-by":"publisher","DOI":"10.1002\/14651858.CD014510","article-title":"Immunosuppressive and immunomodulatory therapies for idiopathic inflammatory myopathies","author":"Raaphorst","year":"2023","journal-title":"Cochrane Database of Systematic Reviews"}],"container-title":["Cochrane Database of Systematic Reviews"],"original-title":[],"language":"en","deposited":{"date-parts":[[2026,4,14]],"date-time":"2026-04-14T15:35:16Z","timestamp":1776180916000},"score":1,"resource":{"primary":{"URL":"http:\/\/doi.wiley.com\/10.1002\/14651858.CD015855"}},"subtitle":[],"editor":[{"name":"Cochrane Central Editorial Service","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"editor"}]}],"short-title":[],"issued":{"date-parts":[[2025,8,11]]},"references-count":336,"journal-issue":{"issue":"8","published-online":{"date-parts":[[2025,8]]}},"URL":"https:\/\/doi.org\/10.1002\/14651858.cd015855","relation":{},"ISSN":["1465-1858"],"issn-type":[{"value":"1465-1858","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,8,11]]}}}